			ALLE	RGY/IMI	MUNOLOGY					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Allergic reaction	1, 2, 3, or 4	LLT : Allergic reaction	PT:	HLT : Allergic conditions NEC	HLGT : Allergic conditions	Pr : Immune system	SSC1: HYPERSENSI		
	Hypersensitivity	1, 2, 3, or 4	LLT: Hypersensitivit y	ty Nos	. Allergic conditions NEO	TEST . Allergic conditions	disorders	TIVITY REACTIONS		
	Drug fever	1 (drug fever <38°C) 2 (drug fever > or = 38°C)	LLT : Drug fever	PT : Pyrexia	<u>HLT</u> : Febrile disorders	HLGT : Body temperature conditions	Pr : General disorders and administration site conditions			
	Rash	1	LLT : Rash	PT : Rash NOS	HLT : Rashes, eruptions and exanthems NEC	HLGT: Epidermal and dermal conditions	Pr : Skin and subcutaneous tissue disorders			
	Allergic rash	1	lf you	need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76	madhoc Serres	.0 - MedDRA),			
Adverse Event Allergic reaction/hypersensitivity (including drug fever)  Grade 1: transient rash, drug fever <38 degrees C (<100.4 degrees F)  Grade 2: urticaria, drug fever >= 38 degrees C (>= 100.4 degrees F), and/or asymptomatic bronchospasm  Grade 3: symptomatic bronchospasm, requiring parenteral medication(s),	Hypersensitivity: rash	1			Tel: +33 (0)6 71 76 Tel: +33 (0)6 73 51 or send an email to <u>info@pl</u>	37 96				
with or without urticaria; allergy-related edema/angioedema  Grade 4: anaphylaxis  Grade 5: death related to toxicity  Note: Isolated urticaria, in the absence of other manifestations of an allergic or hypersensitivity reaction, is graded in the	Urticaria	2	LLT: Urticaria	PT : Urticaria		HLGT: Angioedema and urticaria	Pr : Skin and subcutaneous tissue disorders	SSC1:		
DERMATOLOGY/SKIN category.	Allergic urticaria	2	LLT : Allergic urticaria	NOS	<u>HLT</u> : Urticarias	HLGT : Allergic conditions	Sec <sub>1</sub> : Immune system	S		
		LIT · Pach			TEST . Allergic conditions	disorders				
	Asymptomatic Bronchospasm	2	LLT:	PT:	HLT:	HLGT:	Pr:	SSC <sub>1</sub> :	SSC <sub>2</sub> :	
	Symptomatic Bronchospasm	3								
	Allergy-related	3	LLT : Allergic	PT : Allergic	HLT : Allergic conditions NEC	HLGT: Allergic conditions	Pr : Immune system disorders	SSC <sub>1</sub> :		
	edema	Ĭ	edema	oedema NOS	HLT : Oedema NEC	HLGT : General system disorders NEC	Sec <sub>1</sub> : General disorders and administration site conditions	OEDEMA		

		Allergy-related	3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	SSC <sub>2</sub> :	SSC <sub>3</sub> :
λĐΩ		angioedema			<u> </u>		HLGT:	Sec₁:			
Category: ALLERGY/IMMUNOLOGY		Allergic rhinitis	1or 2	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
/IMML	Adverse Event Allergic rhinitis (including sneezing, nasal stuffiness, postnasal drip)	Allergic minitis	101 2	<u></u> .	<u>F1</u> .	HLT:	HLGT:	Sec₁:			
ERGY.	Grade 1: mild, not requiring treatment Grade 2: moderate, requiring treatment N/A Grade 3:	Sneezing	1or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
y: ALL	N/A Grade 4: N/A Grade 5:	Nasal stuffiness	1or 2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
ategor		Postnasal drip	1or 2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
0	Adverse Event Autoimmune reaction  Grade 1: serologic or other evidence of autoimmune reaction but patient is asymptomatic (e.g., vitiligo), all organ function is normal and no treatment is required  Grade 2: evidence of autoimmune reaction involving a non-essential organ or function (e.g., hypothyroidism), requiring treatment other than immunosuppressive drugs  Grade 3: reversible autoimmune reaction involving function of a major organ or other toxicity (e.g., transient colitis or anemia), requiring short-term immunosuppressive treatment  Grade 4: autoimmune reaction causing major grade 4 organ dysfunction; progressive and irreversible reaction; long-term administration of high-dose immunosuppressive therapy required  Grade 5: death related to toxicity  Note: Also consider Hypothyroidism, Colitis, Hemoglobin, Hemolysis.	Autoimmune reaction	1, 2, 3, or 4	LLT : Autoimmune disorder NOS	PT: Autoimmune disorder NOS	HLT : Autoimmune disorders NEC	HLGT : Autoimmune disorders	Pr : Immune system disorders			
	Adverse Event Serum sickness  N/A Grade 1: N/A Grade 2: Grade 3: present N/A Grade 4: Grade 5: death related to toxicity	Serum sickness	3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HGLT</u> :	<u>Pr</u> :			
	Urticaria is graded in the DERMATOLOGY/SKIN category if it occurs as an isolated symptom. If it occurs with other manifestations of allergic or hypersensitivity reaction, grade as Allergic reaction/hypersensitivity above										

Adverse Event Vasculitis  Grade 1: mild, not requiring treatment Grade 2: symptomatic, requiring medication Grade 3: requiring steroids Grade 4: ischemic changes or requiring amputation Grade 5: death related to toxicity	Vasculitis	1, 2, 3, or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> : <u>Sec</u> <sub>1</sub> :			
Adverse Event Allergy-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
			AUI	DITORY	HEARING					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	III OT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Conductive hearing loss is graded as Middle ear/hearing in the AUDITORY/HEARING category										
Earache is graded in the PAIN category										
	External Auditory	1. 2. 3 or	LLT : Otitis	PT : Otitis	HLT : Ear infections	HLGT : Infections - pathogen class unspecified	Pr : Infections and infestations			
Adverse Event External Auditory Canal	Canal	4	externa (excl boil of meatus)	externa NOS	<u>HLT</u> : External ear infections and inflammations	HLGT : External ear disorders (excl congenital)	Sec <sub>1</sub> : Ear and labyrinth disorders			
Grade 1: external otitis with erythema or dry desquamation Grade 2: external otitis with moist desquamation Grade 3: external otitis with discharge, mastoiditis Grade 4: necrosis of the canal soft tissue or bone Grade 5: death related to toxicity  Note: Changes associated with radiation to external ear (pinnae) are graded under Radiation dermatitis in the DERMATOLOGY/SKIN category.	External otitis	1, 2 or 3	If you	need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76 Tel: +33 (0)6 73 51 or send an email to info@pl	madhoc Serres 8 88 17 37 96	.0 - MedDRA),			
	Mastoiditis	3	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
	masioidilis		<u></u> .	<u></u> .	HLT:	HLGT:	Sec₁:			
o l	Inner ear/hearing	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			

1 10	i			•				,			
AUDITORY/HEARING		Inner ear	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
RY/HE	Adverse Event Inner ear/hearing  Grade 1: hearing loss on audiometry only	Hearing	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
DIITO	Grade 2: tinnitus or hearing loss, not requiring hearing aid or treatment Grade 3: tinnitus or hearing loss, correctable with hearing aid or treatment Grade 4: severe unilateral or bilateral hearing loss (deafness), not	Hearing loss	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
ry: Al	correctable  Grade 5: death related to toxicity	Tinnitus	2 or 3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Category:		Tillinus	2 01 3	<u>LL1</u> .	<u></u>	<u>HLT</u> :	HLGT:	Sec <sub>1</sub> :			
		Deafness	4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
		Middle ear/hearing	1, 2, 3 or 4	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
	Adverse Event Middle ear/hearing	Serous otitis	1, 2 or 3	<u>CC1</u> .	<u></u>	HLT:	HLGT:	Sec <sub>1</sub> :			
	Grade 1: serous otitis without subjective decrease in hearing Grade 2: serous otitis or infection requiring medical intervention; subjective	Rupture of tympanic membrane	2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	decrease in hearing; rupture of tympanic membrane with discharge  Grade 3: otitis with discharge, mastoiditis or conductive hearing loss  Grade 4: necrosis of the canal soft tissue or bone	Mastoiditis	3	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Grade 5: death related to toxicity	iviasioidilis	3	<u></u> .	<u>F1</u> .	HLT:	HLGT:	Sec <sub>1</sub> :			
		Conductive hearing loss	3	LLT: Conductive hearing loss	PT: Conductive deafness	HLT : Hearing losses	HLGT : Hearing disorders	Pr : Ear and labyrinth disorders			
	Adverse Event Auditory/Hearing-Other (Specify,)  Grade 1: mild										
	Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
				BLOC	DD/BON	E MARROW					
	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	III OT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Adverse Event Bone marrow cellularity  Grade 1: mildly hypocellular or <=25% reduction from normal cellularity for age  Grade 2: moderately hypocellular or <25. <= 50% reduction from normal	Bone marrow cellularity	1, 2 or 3	LLT : Bone marrow hypocellular	PT : Bone marrow depression NOS	HLT : Marrow depression and hypoplastic anaemias	HLGT : Anaemias nonhaemolytic and marrow depression	Pr : Blood and lymphatic system disorders	BONE	SSC <sub>2</sub> : SECONDARY IMMUNOCOM PROMISED STATE	

Coracle 2: moderately nypocellular or >25 - <= 50% reduction from normal cellularity for age or >2 but <4 weeks to recovery of normal bone marrow cellularity  Coracle 3: severely hypocellular or >50 - <=75% reduction in cellularity for age or 4 - 6 weeks to recovery of normal bone marrow cellularity  Coracle 4: aplasia or >6 weeks to recovery of normal bone marrow cellularity  Coracle 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> : Haematological disorders	HLGT : Haematological disorders NEC	,	BONE MARROW DEPRESSION		
Note: Grade Bone marrow cellularity only for changes related to treatment, not disease. Normal ranges: children (<=18 years) 90% cellularity average; younger adults (19-59) 60-70% cellularity average; older adults (>60 years) 50% cellularity average.		4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> : Marrow depression and hypoplastic anaemias	HLGT : Anaemias nonhaemolytic and marrow depression	Pr : Blood and lymphatic system disorders	DONE	SSC <sub>2</sub> : SECONDARY IMMUNOCOM PROMISED STATE	
Adverse Event CD4 count  Grade 1: < LLN - 500/mm(3)  Grade 2: 200 - <500/mm(3)  Grade 3: 50 - <200/mm(3)  Grade 4: <50/mm(3)  Grade 5: death related to toxicity	CD4 count	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT : Immunology and allergy investigations	<u>Pr</u> : Investigations			
Adverse Event Haptoglobin  Grade 1: decreased N/A Grade 2: Grade 3: absent N/A Grade 4: Grade 5: death related to toxicity	Haptoglobin	1 or 3	шт:	<u>PT</u> :	HLT : Haem metabolism analyses	HLGT : Metabolic, nutritional and blood gas investigations	<u>Pr</u> : Investigations			
Adverse Event Hemoglobin  Grade 1: < LLN - 10.0 g/dL; < LLN - 100 g/L; < LLN - 6.2 mmol/L  Grade 2: 8.0 - <10.0 g/dL; 80 - <100 g/L; 4.9 - <6.2 mmol/L  Grade 3: 6.5 - <8.0 g/dL; 65 - <8.0 g/L; 4.0 - <4.9 mmol/L  Grade 4: <6.5 g/dL; <65 g/L; <4.0 mmol/L  Grade 5: death related to toxicity	Hemoglobin	1, 2, 3 or 4	LLT: Hemoglobin decreased	PT: Haemoglobin decreased	<u>HLT</u> : Red blood cell analyses	HLGT: Haematology investigations (incl blood groups)	<u>Pr</u> : Investigations			
Adverse Event Hemoglobin for leukemia studies or bone marrow infiltrative/myelophthisic processes, if specified in the protocol.  Grade 1: 10 - <25% decrease from pretreatment Grade 2: 25 - <50% decrease from pretreatment Grade 3: 50 - <75% decrease from pretreatment Grade 4: >= 75% decrease from pretreatment Grade 5: death related to toxicity  Note: The above criteria may be used for leukemia studies or bone marrow infiltrative/myelophthisic process if the protocol so specifies.	Hemoglobin	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			

Adverse Event Hemolysis (e.g., immune hemolytic anemia, drug related hemolysis, other)  Grade 1: only laboratory evidence of hemolysis [e.g., direct antiglobulin test (DAT, Coombs') schistocytes] Grade 2: evidence of red cell destruction and >= 2gm decrease in hemoglobin, no transfusion Grade 3: requiring transfusion and/or medical intervention (e.g., steroids) Grade 4: catastrophic consequences of hemolysis (e.g., renal failure, hypotension, bronchospasm, emergency splenectomy) Grade 5: death related to toxicity  Note: Also consider Haptoglobin, Hemoglobin.	Hemolysis	1, 2, 3 or 4	LLT: Hemolysis	PT: Haemolysis NOS	HLT : Haemolyses NEC	HLGT: Haemolyses and related conditions	Pr : Blood and lymphatic system disorders		
Adverse Event Leukocytes (total WBC)  Grade 1: < LLN - 3.0 x 10e9/L; < LLN - 3000/mm(3)  Grade 2: >= 2.0 - <3.0 x 10e9/L; >=2000 - <3000/mm(3)	Leukocytes	1, 2, 3 or 4	<u>LLT</u> :					SSC <sub>1</sub> : BLOOD DYSCRASIAS/	
Grade 3: >= 1.0 - <2.0 x 10e9/L; >= 1000 - <2000/mm(3) Grade 4: <1.0 x 10e9/L; <1000/mm(3) Grade 5: death related to toxicity	WBC	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	BONE MARROW DEPRESSION	
Adverse Event Leukocytes (total WBC) for BMT studies, if specified in the protocol.  Grade 1: >= 2.0 - <3.0 x 10e9/L; >= 2000 - <3000/mm(3) Grade 2: >= 1.0 - <2.0 x 10e9/L; >= 1000 - <2000/mm(3)	Leukocytes	1, 2, 3 or 4	LLT : Leukocyte count decreased	PT : White blood cell	HLT : White blood cell analyses	HLGT: Haematology investigations (incl blood	Pr : Investigations	SSC1: BLOOD DYSCRASIAS/	
Grade 2: >= 1.0 - <2.0 x 10e9/t; >= 1000 - <2000/mm(3) Grade 3: >= 0.5 - <1.0 x 10e9/t; >= 500 - <1000/mm(3) Grade 4: <0.5 x 10e9/t; <500/mm(3) Grade 5: death related to toxicity	WBC	1, 2, 3 or 4	LLT: WBC decreased	count decreased	TELL . The blood cell allalyses	groups)		BONE MARROW DEPRESSION	
Adverse Event Leukocytes (total WBC) for pediatric BMT studies (using age, race and sex normal values), if specified in the protocol.  Grade 1: >=75 - <100% LLN Grade 2: >=50 - <75% LLN	Leukocytes	1, 2, 3 or 4	LLT : Leukocyte count decreased	PT : White blood cell	HLT : White blood cell analyses	HLGT: Haematology investigations (incl blood	Pr : Investigations	SSC <sub>1</sub> : BLOOD DYSCRASIAS/	
Grade 3: >=25 - 50% LLN Grade 4: <25% LLN Grade 5: death related to toxicity	WBC	1, 2, 3 or 4	LLT : WBC decreased	count decreased		groups)	_	BONE MARROW DEPRESSION	
Adverse Event Lymphopenia  Grade 1: < LLN - 1.0 x 10e9/L; < LLN - 1000/mm(3)  Grade 2: >= 0.5 - <1.0 x 10e9/L; >= 500 - <1000/mm(3)  Grade 3: <0.5 x 10e9/L; <500/mm(3)  NA Grade 4:  Grade 5: death related to toxicity	Lymphopenia	1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT : White blood cell disorders	Pr : Blood and lymphatic system disorders	SSC.: BLOOD DYSCRASIAS/ BONE MARROW DEPRESSION	

Category: BLOOD/BONE MARROW	Adverse Event Lymphopenia for pediatric BMT studies (using age, race and sex normal values), if specified in the protocol.  Grade 1: >=75 - <100% LLN Grade 2: >=50 - <75% LLN Grade 3: >=25 - <50% LLN Grade 4: <25% LLN Grade 5: Death due to toxicity	Lymphopenia	1, 2, 3 or 4		PT: Lymphopenia	HLT : Leukopenias NEC	HLGT : White blood cell disorders	Pr : Blood and lymphatic system disorders	SSC1: BLOOD DYSCRASIAS/ BONE MARROW DEPRESSION	
D/BONE	Adverse Event Neutrophils/granulocytes (ANC/AGC)	Neutrophils	1, 2, 3 or 4	<u>LLT</u> :						
ory: BLOO	Grade 1: >= 1.5 - <2.0 x 10e9/L; >= 1500 - <2000/mm(3) Grade 2: >= 1.0 - <1.5 x 10e9/L; >= 1000 - <1500/mm(3) Grade 3: >= 0.5 - <1.0 x 10e9/L; >= 500 - <1000/mm(3) Grade 4: <0.5 x 10e9/L; <500/mm(3) Grade 5: death related to toxicity	Granulocytes	1, 2, 3 or 4	LLT : Granulocyte count decreased	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	
Catego	Adverse Event Neutrophils/granulocytes (ANC/AGC) for BMT studies, if specified in the protocol.  Grade 1: >= 1.0 - <1.5 x 10e9/L; >= 1000 - <1500/mm(3)	Neutrophils	1, 2, 3 or 4	<u>LLT</u> :						
	Grade 2: >= 0.5 - <1.0 x 10e9/L; >= 500 - <1000/mm(3) Grade 3: >= 0.1 - <0.5 x 10e9/L; >= 100 - <500/mm(3) Grade 4: <0.1 x 10e9/L; <100/mm(3) Grade 5: death related to toxicity	Granulocytes	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>4</sub> :	
	Adverse Event Neutrophils/granulocytes (ANC/AGC) for leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.  Grade 1: 10 - <25% decrease from baseline	Neutrophils	1, 2, 3 or 4	<u>LLT</u> :						
	Grade 2: 25 - <50% decrease from baseline Grade 3: 50 - <75% decrease from baseline Grade 4: >= 75% decrease from baseline Grade 5: death related to toxicity	Granulocytes	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	
	Adverse Event Platelets  Grade 1: < LLN - <75.0 x 10e9/L; < LLN - 75,000/mm(3)  Grade 2: >= 50.0 - <75.0 x 10e9/L; >= 50,000 - <75,000/mm(3)  Grade 3: >=10.0 - <50.0 x 10e9/L; >=10,000 - <50,000/mm(3)  Grade 4: <10.0 x 10e9/L; <10,000/mm(3)  Grade 5: death related to toxicity	Platelets	1, 2, 3 or 4	шт:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	
	Adverse Event Platelets for BMT studies, if specified in the protocol.  Grade 1: >= 50.0 - <75.0 x 10e9/L; >= 50,000 - <75,000/mm(3)  Grade 2: >= 20.0 - <50.0 x 10e9/L; >= 20,000 - <50,000/mm(3)  Grade 3: >= 10.0 - <20.0 x 10e9/L; >= 10,000 - <20,000/mm(3)  Grade 4: <10.0 x 10e9/L; <10,000/mm(3)  Grade 5: death related to toxicity	Platelets	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:	SSC.:	

Adverse Event Platelets for leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.  Grade 1: 10 - <25% decrease from baseline Grade 2: 25 - <50% decrease from baseline Grade 3: 50 - <75% decrease from baseline Grade 4: >= 75% decrease from baseline Grade 5: death related to toxicity	Platelets	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>1</sub> :	
Adverse Event Transfusion: Platelets  N/A Grade 1: N/A Grade 2: Grade 3: yes Grade 4: platelet transfusions and other measures required to improve platelet increment; platelet transfusion refractoriness associated with lifethreatening bleeding. (e.g., HLA or cross matched platelet transfusions) Grade 5: death related to toxicity  Note: Also consider Platelets	Platelets transfusion	3 or 4	<u>LLT</u> : Platelets transfusion	PT : Platelets transfusion	<u>HLT</u> : Blood and blood product treatment	<u>HLGT</u> : Haematological and lymphoid tissue therapeutic procedures	Pr : Surgical and medical procedures		
Adverse Event Transfusion: Platelets for BMT studies, if specified in the protocol.  Grade 1: 1 platelet transfusion in 24 hours Grade 2: 2 platelet transfusions in 24 hours Grade 3: >= 3 platelet transfusions in 24 hours Grade 4: platelet transfusions and other measures required to improve platelet increment; platelet transfusion refractoriness associated with life-threatening bleeding, (e.g., HLA or cross matched platelet transfusions) Grade 5: death related to toxicity  Note: Also consider Platelets	Platelets transfusion	3 or 4	<u>LLT</u> : Platelets transfusion	PT : Platelets transfusion	<u>HLT</u> : Blood and blood product treatment	HLGT: Haematological and lymphoid tissue therapeutic procedures	Pr : Surgical and medical procedures		
Adverse Event Transfusion: pRBCs  N/A Grade 1: N/A Grade 2: Grade 3: yes N/A Grade 4: Grade 5: death related to toxicity  Note: Also consider Hemoglobin		3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr : Surgical and medical procedures		
Adverse Event Transfusion: pRBCs for BMT studies, if specified in the protocol.  Grade 1: <= 2 u pRBC in 24 hours elective or planned Grade 2: 3 u pRBC in 24 hours elective or planned Grade 3: >= 4 u pRBC in 24 hours elective or planned Grade 3: >= 4 u pRBC in 24 hours elective or planned Grade 4: hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin Grade 5: death related to toxicity  Note: Also consider Hemoglobin	Transfusion pRBCs	1, 2, 3 or 4	LLT : Packed red blood cell transfusion	PT : Packed red blood cell transfusion	<u>HLT</u> : Blood and blood product treatment	HLGT : Haematological and lymphoid tissue therapeutic procedures	Pr : Surgical and medical procedures		

Adverse Event Transfusion: pRBCs for pediatric BMT studies, if specified in the protocol.  Grade 1: <=15mL/kg in 24 hours elective or planned Grade 2: >15 - <=30mL/kg in 24 hours elective or planned Grade 3: >30mL/kg in 24 hours Grade 4: hemorrhage or hemolysis associated with life-threatening anemia; medical intervention required to improve hemoglobin Grade 5: death related to toxicity  Note: Also consider Hemoglobin  Adverse Event Blood/Bone Marrow-Other (Specify,)	Transfusion pRBCs	1, 2, 3 or 4	ш:	<u>PT</u> :	HLT : Blood and blood product treatment	HLGT:	<u>Pr</u> :			
Grade 1: mild  Grade 2: moderate  Grade 3: severe  Grade 4: life-threatening or disabling  Grade 5: death related to toxicity										
		CA	RDIOVA	SCULA	R (ARRHYTHMIA)					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Conduction abnormality/Atrioventricular heart block  Grade 1: asymptomatic, not requiring treatment (e.g., Mobitz type I second-degree AV block, Wenckebach)	Conduction abnormality/Atrio ventricular heart block	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT : Cardiac arrhythmias	Pr : Cardiac disorders	SSC1: CARDIAC ISCHAEMIA		
Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic and requiring treatment (e.g., Mobitz type II second- degree AV block, third-degree AV block) Grade 4: life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock) Grade 5: death related to toxicity	Conduction abnormality	1, 2, 3 or 4	If you	need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76 Tel: +33 (0)6 73 51 or send an email to info@pl	madhoc Serres 5 88 17 1 37 96	.0 - MedDRA),			
Adverse Event Nodal/junctional arrhythmia/dysrhythmia  Grade 1: asymptomatic, not requiring treatment		1, 2, 3 or 4		<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr : Cardiac disorders			
Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic and requiring treatment Grade 4: life-threatening (e.g., arrhythmia associated with CHF,		1, 2, 3 or 4	<u>LLT</u> :							
hypotension, syncope, shock)  Grade 5: death related to toxicity	Dysrhythmia	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Arrhythmia	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			

	Adverse Event Palpitations  Grade 1: present N/A Grade 2: N/A Grade 3: N/A Grade 4: N/A Grade 5:  Note: Grade palpitations only in the absence of a documented arrhythmia.		1	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
	Adverse Event Prolonged QTc interval (QTc > 0.48 seconds)  Grade 1: asymptomatic, not requiring treatment Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic and requiring treatment Grade 4: life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock) Grade 5: death related to toxicity	Prolonged QTc interval (QTc > 0.48 seconds)		шт:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Sinus bradycardia  Grade 1: asymptomatic, not requiring treatment Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic and requiring treatment	Sinus bradycardia		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
(ARRHYTHMIA)	Grade 4: life-threatening (e.g., arrhythmia associated with CHF,	Bradycardia		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> : Rate and rhythm disorders NEC	HLGT:	<u>Pr</u> :		
	Adverse Event Sinus tachycardia  Grade 1: asymptomatic, not requiring treatment Grade 2: symptomatic, but not requiring treatment		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
OVASCUL	Grade 3: symptomatic and requiring treatment of underlying cause N/A Grade 4: Grade 5: death related to toxicity		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
Category: CARDIOVASCULAR	Adverse Event Supraventricular arrhythmias (SVT/atrial fibrillation/flutter)		1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Cate	Grade 1: asymptomatic, not requiring treatment Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic and requiring treatment	SVT		<u>LLT</u> :						
	Grade 4: life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock) Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> : Cardiac arrhythmias	<u>Pr</u> :		

		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT : Supraventricular arrhythmias	HLGT : Cardiac arrhythmias	Pr : Cardiac disorders			
Syncope (fainting) is graded in the NEUROLOGY category										
Adverse Event Vasovagal episode  N/A Grade 1: Grade 2: present without loss of consciousness	Vasovagal episode	2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 3: present with loss of consciousness N/A Grade 4: Grade 5: death related to toxicity		3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Ventricular arrhythmia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr : Cardiac disorders	SSC1: ARREST (CARDIAC)	SSC <sub>2</sub> : CARDIAC ISCHAEMIA	
Adverse Event Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr : Cardiac disorders			
tachycardia)  Grade 1: asymptomatic, not requiring treatment  Grade 2: symptomatic, but not requiring treatment		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr : Cardiac disorders			
Grade 3: symptomatic and requiring treatment Grade 4: life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock) Grade 5: death related to toxicity	Trigeminy		LLT:	<u>PT</u> :	HLT : Ventricular arrhythmias and cardiac arrest	HLGT : Cardiac arrhythmias	Pr : Cardiac disorders			
		1, 2, 3 or		<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC1:	SSC <sub>2</sub> :	
		4		<u> </u>	HLT : Autonomic nervous system disorders	HLGT:	Sec. : Nervous system disorders	(CARDIAC)	ISCHAEMIA	
Adverse Event Cardiovascular/Arrhythmia-Other (Specify,)  Grade 1: asymptomatic, not requiring treatment Grade 2: symptomatic, but not requiring treatment Grade 3: symptomatic, and requiring treatment of underlying cause Grade 4: life-threatening (e.g., arrhythmia associated with CHF, hypotension, syncope, shock) Grade 5: death related to toxicity										
		(	CARDIO\	/ASCUL	AR (GENERAL)					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC

Adverse Event Acute vascular leak syndrome  N/A Grade 1: Grade 2: symptomatic, but not requiring fluid support	Acute vascular		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 3: respiratory compromise or requiring fluids Grade 4: life-threatening; requiring pressor support and/or ventilatory support Grade 5: death related to toxicity	leak syndrome				HLT:	<u>HLGT</u> :	Sec <sub>1</sub> :		
Adverse Event Cardiac-ischemia/infarction	Cardiac- ischemia/infarctio	1, 2, 3 or	IIIT :	<u>PT</u> :	HLT:	HLGT:	Pr : Cardiac disorders	· <u>SSC</u> 1:	
Grade 1: non-specific T-wave flattening or changes Grade 2: asymptomatic, ST- and T- wave changes suggesting ischemia Grade 3: angina without evidence of infarction Grade 4: acute myocardial infarction	n	4			<u>HLT</u> :	HLGT:	Sec₁: Vascular disorders		
Grade 5: death related to toxicity			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		<u> </u>
Adverse Event Cardiac left ventricular function  Grade 1: asymptomatic decline of resting ejection fraction of >=10% but <20% of baseline value; shortening fraction >=24% but <30%  Grade 2: asymptomatic but resting ejection fraction below LLN for laboratory or decline of resting ejection fraction >= 20% of baseline value; <24% shortening fraction  Grade 3: CHF responsive to treatment  Grade 4: severe or refractory CHF or requiring intubation  Grade 5: death related to toxicity	Cardiac left ventricular function		ш:	<u>PT</u> :	HLT:	HLGT:	Pr:	<u>ssc.</u> ;	
CNS cerebrovascular ischemia is graded in the NEUROLOGY category									1
Adverse Event Cardiac troponin I (cTnI)  N/A Grade 1: N/A Grade 2: Grade 3: levels consistent with unstable angina as defined by the manufacturer Grade 4: levels consistent with myocardial infarction as defined by the manufacturer Grade 5: death related to toxicity	Cardiac troponin I (cTnI)	3 or 4	LLT:	PT:	HLT:	HLGT : Enzyme investigations NEC	Pr:		
Adverse Event Cardiac troponin T (cTnT)  Grade 1: >=0.03 - <0.05 ng/mL  Grade 2: >= 0.05 - <0.1 ng/mL  Grade 3: >= 0.1 - <0.2 ng/mL  Grade 4: >= 0.2 ng/mL  Grade 5: death related to toxicity	Cardiac troponin T (cTnT)		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:		
					<u>HLT</u> :	HLGT:	<u>Pr</u> :		_ <del></del>

		<u>-</u> .							_		
		Edema	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :	SSC1:	SSC <sub>2</sub> :	
	Adverse Event Edema  Grade 1: asymptomatic, not requiring therapy					HLT:	HLGT:	Sec₂:			
	Grade 2: symptomatic, requiring therapy Grade 3: symptomatic edema limiting function and unresponsive to therapy or requiring drug discontinuation			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Grade 4: anasarca (severe generalized edema) Grade 5: death related to toxicity					HLT:	HLGT:	<u>Pr</u> :			
				LLT:	<u>PT</u> :	HLT : Heart failure signs and symptoms	HLGT:	Sec <sub>1</sub> :	SSC <sub>1</sub> :	SSC <sub>2</sub> :	
						HLT:	HLGT:	Sec₂:			
	Adverse Event Hypertension  Grade 1: asymptomatic, transient increase by >20 mmHg (diastolic) or to > 150/100* if previously WNL; not requiring treatment  Grade 2: recurrent or persistent or symptomatic increase by > 20 mmHg (diastolic) or to > 150/100* if previously WNL; not requiring treatment  Grade 3: requiring therapy or more intensive therapy than previously	Hypertension	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Grade 4: hypertensive crisis  Grade 5: death related to toxicity  Note: * For pediatric patients, use age and sex appropriate normal values >95th percentile ULN.			LLT:	<u>PT</u> :	HLT:	<u>HLGT</u> :	<u>Pr</u> :			
	Adverse Event Hypotension  Grade 1: changes, but not requiring therapy (including transient orthostatic hypotension)  Grade 2: requiring brief fluid replacement or other therapy but not hospitalization; no physiologic consequences	Hypotension	1, 2, 3 or 4	<u>LLT</u> : Hypotension	PT: Hypotension NOS	HLT : Vascular hypotensive disorders	HLGT: Decreased and nonspecific blood pressure disorders and shock	Pr : Vascular disorders	SSC1: ANAPHYLAXI S	SSC <sub>2</sub> : CARDIAC ISCHAEMIA	
NERA	Grade 3: requiring therapy and sustained medical attention, but resolves without persisting physiologic consequences  Grade 4: shock (associated with acidemia and impairing vital organ function due to tissue hypoperfusion)  Grade 5: death related to toxicity		1	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
CULAR		Hypovolemic shock		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Adverse Event Myocarditis  N/A Grade 1:  N/A Grade 2:	Myocarditis	3 or 4	LLT: Myocarditis	PT: Myocarditis NOS	HLT : Noninfectious myocarditis	HLGT: Myocardial disorders	Pr : Cardiac disorders			

_	la calaura di calaura			1		T	1			
Catego	Grade 3: CHF responsive to treatment Grade 4: severe or refractory CHF Grade 5: death related to toxicity		3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	
			1, 2, 3 or	IIT:	<u>PT</u> :	HLT:	HLGT:	Pr: Injury, poisoning and procedural complications		
	Adverse Event Operative injury of vein/artery		4	<u></u>	<u></u>	HLT:	HLGT:	Sec <sub>1</sub> : Vascular disorders		
	Grade 1: primary suture repair for injury, but not requiring transfusion Grade 2: primary suture repair for injury, requiring transfusion		1, 2, 3 or	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> : Injury, poisoning and procedural complications		
	Grade 3: vascular occlusion requiring surgery or bypass for injury Grade 4: myocardial infarction; resection of organ (e.g., bowel, limb) Grade 5: death related to toxicity		4			HLT:	HLGT:	Sec <sub>1</sub> : Vascular disorders		
			3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		Myocardial infarction	4	LLT: Myocardial infarction	PT: Myocardial infarction	HLT : Ischaemic coronary artery disorders	HLGT : Coronary artery disorders	Pr : Cardiac disorders		
	Adverse Event Pericardial effusion/pericarditis	Pericardial effusion/pericardit is	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Grade 1: asymptomatic effusion, not requiring treatment Grade 2: pericarditis (rub, ECG changes, and/or chest pain) Grade 3: with physiologic consequences Grade 4: tamponade (drainage or pericardial window required)		2, 3 or 4		<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Grade 5: death related to toxicity		2, 3 01 4	ELT.	<u>F1</u> .	HLT:	HLGT:	Sec <sub>1</sub> : Infections and infestations		
	Adverse Event Peripheral arterial ischemia  N/A Grade 1: Grade 2: brief episode of ischemia managed non-surgically and without permanent deficit Grade 3: requiring surgical intervention Grade 4: life-threatening or with permanent functional deficit (e.g., amputation) Grade 5: death related to toxicity	Peripheral arterial ischemia	2, 3 or 4	LLT:	<u>PT</u> :	HLT :	HLGT:	<u>Pr</u> :		
	Adverse Event Phlebitis (superficial)  N/A Grade 1: Grade 2: present N/A Grade 3: N/A Grade 4: N/A Grade 5:  Note: Injection site reaction is graded in the DERMATOLOGY/SKIN category. Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category.	Phlebitis (superficial)		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		

					1	1	1			
Syncope (fainting) is graded in the NEUROLOGY category										
	Thrombosis/emb olism	2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC₁:		
Adverse Event Thrombosis/embolism  N/A Grade 1:		2 or 3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Grade 2: deep vein thrombosis, not requiring anticoagulant Grade 3: deep vein thrombosis, requiring anticoagulant therapy Grade 4: embolic event including pulmonary embolism		4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 5: death related to toxicity		4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC₁:		
					HLT:	HLGT:	<u>Sec.</u> :	THROMBOSIS		
Vein/artery operative injury is graded as Operative injury of vein/artery in the CARDIOVASCULAR (GENERAL) category										
Adverse Event Visceral arterial ischemia (non-myocardial)  N/A Grade 1: Grade 2: brief episode of ischemia managed non-surgically and without permanent deficit Grade 3: requiring surgical intervention Grade 4: life-threatening or with permanent functional deficit (e.g., resection of ileum) Grade 5: death related to toxicity	Visceral arterial ischemia (non- myocardial)		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Cardiovascular/General-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
			C	COAGUI	ATION					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Note: See the HEMORRHAGE category for grading the severity of bleeding events.										
Adverse Event DIC (disseminated intravascular coagulation)  N/A Grade 1:  N/A Grade 2:  Grade 3: laboratory findings present with no bleeding	DIC	3 or 4	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			

		10 UI 4						•	
Grade 4: laboratory findings and bleeding Grade 5: death related to toxicity  Note: Must have increased fibrin split products or D-dimer in order to grade as DIC. Also consider Platelets.		3 01 4	LLT:	· ·	HLT:	HLGT:	<u>Sec.</u> ;		
Adverse Event Fibrinogen  Grade 1: >= 0.75 - <1.0 x LLN Grade 2: >= 0.5 - <0.75 x LLN Grade 3: >= 0.25 - <0.5 x LLN Grade 4: <0.25 x LLN Grade 5: death related to toxicity	Fibrinogen	1, 2, 3 or 4		need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76 Tel: +33 (0)6 73 51 or send an email to info@pl	madhoc Serres 888 17 37 96	.0 - MedDRA),		
Adverse Event Fibrinogen for leukemia studies or bone marrow infiltrative/myelophthisic process, if specified in the protocol.  Grade 1: <20% decrease from pretreatment value or LLN Grade 2: >= 20 - <40% decrease from pretreatment value or LLN Grade 3: >= 40 - <70% decrease from pretreatment value or LLN Grade 5: >= 40 - 60% decrease from pretreatment value or LLN Grade 5: death related to toxicity	Fibrinogen	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
	Partial thromboplastin time (PTT)		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Phelbitis is graded in the CARDIOVASCULAR (GENERAL) category									
Adverse Event Prothrombin time (PT)  Grade 1: >ULN - <= 1.5 x ULN Grade 2: > 1.5 - <= 2 x ULN Grade 3: >2 x ULN N/A Grade 4: Grade 5: death related to toxicity  Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category	Prothrombin time (PT)	1, 2 or 3	LLT : Prothrombin time prolonged	PT: Prothrombin time prolonged	<u>HLT</u> : Coagulation and bleeding analyses	HLGT: Haematology investigations (incl blood groups)	<u>Pr</u> : Investigations		
Thrombosis/embolism is graded in the CARDIOVASCULAR (GENERAL) category									
		3 or 4	IIT:	pT ·	HLT:	HLGT:	<u>Pr</u> :		

I	İ	3 UI 4	<u></u> .	<u>  F 1 - </u>		1	T	Ī	i i	Ī
Adverse Event Thrombotic microangiopathy (e.g., thrombotic					HLT:	HLGT:	Sec <sub>1</sub> :			ı
thrombocytopenic purpura/TTP or hemolytic uremic syndrome/HUS)  N/A Grade 1: N/A Grade 2: Grade 3: laboratory findings present without clinical consequences			LLT:		HLT:	HLGT:	<u>Pr</u> :			
Grade 4: laboratory findings and clinical consequences, (e.g., CNS hemorrhage/bleeding or thrombosis/embolism or renal failure) requiring therapeutic intervention Grade 5: death related to toxicity		3 or 4		<u>PT</u> :	HLT:	HLGT:	Sec.:	<u>SSC.</u> :		l
Note: Must have microangiopathic changes on blood smear (e.g., schistocytes, helmet cells, red cell fragments). Also Consider Hemoglobin, Platelets, Creatinine.			<u>LLT</u> :		HLT:	HLGT:	Sec <sub>2</sub> :			
	Hemolytic uremic syndrome	3 or 4	<u>LLT</u> :	- <u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			ſ
			<u>LLT</u> :		HLT:	HLGT:	Sec <sub>1</sub> :			
		1, 2, 3 or	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr : Blood and lymphatic system disorders			ı
Adverse Event Thrombotic microangiopathy (e.g., thrombotic thrombocytopenic purpura/TTP or hemolytic uremic syndrome/HUS) for BMT studies, if specified by the protocol.		4		<u>F1</u> .	HLT:	HLGT:	Sec1: Renal and urinary disorders			<u> </u>
Grade 1: evidence of RBC destruction (schistocytosis) without clinical consequences			<u>LLT</u> :		<u>HLT</u> :	HLGT:	<u>Pr</u> :			Ī
Grade 2: evidence of RBC destruction with elevated creatinine (<=3 x ULN) Grade 3: evidence of RBC destruction with creatinine (>3 x ULN) not requiring dialysis		3 or 4	LLI:	- <u>PT</u> :	HLT:	HLGT:	Sec₁:	<u>SSC</u> <sub>1</sub> :		ı
Grade 4: evidence of RBC destruction with renal failure requiring dialysis and/or encephalopathy Grade 5: death related to toxicity  Note: Must have microangiopathic changes on blood smear (e.g.,			LLT:	<u></u> .	<u>HLT</u> :	HLGT:	<u>Sec</u> <sub>2</sub> :	THROMBOSIS		
schistocytes, helmet cells, red cell fragments). Also Consider Hemoglobin, Platelets, Creatinine.	Hemolytic uremic syndrome	2 05 4	LLT:		HLT:	HLGT : Renal disorders (excl nephropathies)	Pr : Renal and urinary disorders			
		3 or 4	LLT:		<u>HLT</u> :	HLGT: Haemolyses and related conditions	Sec. : Blood and lymphatic system disorders			
Adverse Event Coagulation-Other (Specify,)										İ
Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
	1		CONSTI	TUTION	AL SYMPTOMS	<u>'</u>				

	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Fatigue (lethargy, malaise, asthenia)	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 1: increased fatigue over baseline, but not altering normal activities Grade 2: moderate (e.g., decrease in performance status by 1 ECOG level or 20% Karnofsky or Lansky) or causing difficulty performing some activities Grade 3: severe (e.g., decrease in performance status by >= 2 ECOG levels	Lethargy		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Grade 3. death related to toxicity	Malaise		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Note: See Appendix III for performance status scales.		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Fever (in the absence of neutropenia, where neutropenia is defined as AGC<1.0 x 10e9/L)  Grade 1: 38.0 - 39.0 C (100.4 - 102.2 F) Grade 2: 39.1 - 40.0 C (102.3 - 104.0 F) Grade 3: >40.0 C (>104.0 F) for <24hrs Grade 4: >40.0 C (>104.0 F) for > 24hrs Grade 5: death related to toxicity  Note: The temperature measurements listed above are oral or tympanic. Also consider Allergic reaction/hypersensitivity.	Fever	1, 2, 3 or 4	<u>LLT</u> : Fever	PT : Pyrexia	<u>HLT</u> : Febrile disorders	HLGT : Body temperature conditions	Pr : General disorders and administration site conditions			
Hot flashes/flushes are graded in the ENDOCRINE category										
Adverse Event Rigors, chills  Grade 1: mild, requiring symptomatic treatment (e.g., blanket) or non-narcotic medication Grade 2: severe and/or prolonged, requiring narcotic medication Grade 3: not responsive to narcotic medication N/A Grade 4:	Rigors, chills	1, 2 or 3	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr:			
			<u>LLT</u> :	-	116.1		11.			
Adverse Event Sweating (diaphoresis)	Sweating (diaphoresis)		LLT:							
Adverse Event Sweating (diaphoresis)  Grade 1: mild and occasional Grade 2: frequent or drenching N/A Grade 3: N/A Grade 4: N/A Grade 5:		1 or 2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
NA Grade 4: NA Grade 5:		1 or 2	LLT:							

Adverse Event Weight gain  Grade 1: 5 - <10% Grade 2: 10 - <20% Grade 3: >=20% N/A Grade 4: Grade 5: death related to toxicity	Weight gain		LLT:	<u>PT</u> :	HLT:	<u>HLGT</u> :	<u>Pr</u> :			
Adverse Event Weight gain - Veno-Occlusive Disease (VOD) for BMT studies if specified in the protocol.  Grade 1: >=2 - <5% Grade 2: >=5 - <10% Grade 3: >=10% or as ascites	Weight gain		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
State 3: >= 10% or fluid retention resulting in pulmonary failure  Grade 4: >= 10% or fluid retention resulting in pulmonary failure  Grade 5: death related to toxicity  Note: Also consider Ascites, Edema, Pleural effusion (non-malignant)		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:			
Adverse Event Weight loss  Grade 1: 5 - <10% Grade 2: 10 - <20% Grade 3: >=20% N/A Grade 4: Grade 5: death related to toxicity	Weight loss	1, 2, 3 or 4	LLT : Weight loss	PT: Weight decreased	<u>HLT</u> : Physical examination procedures	HLGT: Physical examination topics	Pr : Investigations			
Adverse Event Constitutional Symptoms-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
			DER	MATOL	OGY/SKIN					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Alopecia  Grade 1: mild hair loss Grade 2: pronounced hair loss N/A Grade 3: N/A Grade 4: N/A Grade 5:	Alopecia	1 or 2	LLT : Alopecia	PT : Alopecia	HLT : Alopecias	HLGT : Skin appendage conditions	Pr : Skin and subcutaneous tissue disorders			

Adverse Event Bruising (in absence of grade 3 or 4 thrombocytopenia)  Grade 1: localized or in dependent area Grade 2: generalized N/A Grade 3: N/A Grade 4: N/A Grade 5:  Note: Bruising resulting from grade 3 or 4 thrombocytopenia is graded as Petechiae/purpura and Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia in the HEMORRHAGE category, not in the DERMATOLOGY/SKIN category.	Bruising (in absence of grade 3 or 4 thrombocytopeni a)		ш:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Dermatitis, focal (associated with high-dose chemotherapy and bone marrow transplant)  Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema Grade 3: confluent moist desquamation, ¾1.5 cm diameter, not confined to skin folds; pitting edema Grade 4: Iskin necrosis or ulceration of full thickness dermis; may include spontaneous bleeding not induced by minor trauma or abrasion			H you	need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)6 73 51 or send an email to info@pl	madhoc Serres 6 88 17 1 37 96	3.0 - MedDRA),		
Adverse Event Dry skin  Grade 1: controlled with emollients Grade 2: not controlled with emollients N/A Grade 3: N/A Grade 4: N/A Grade 5:	Dry skin		<u>шт</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Erythema multiforme (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)	epidermal necrolysis)				HLT:	HLGT:	Sec₁:		
N/A Grade 1: Grade 2: scattered, but not generalized eruption		2 2 1		DT .	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Grade 3: severe or requiring IV fluids (e.g., generalized rash or painful stomatitis)  Grade 4: life-threatening (e.g., exfoliative or ulcerating dermatitis or requiring enteral or parenteral nutritional support)		2, 3 or 4	<u>LL1</u> :	<u>PT</u> :	HLT:	HLGT:	Sec₁:		
Grade 5: death related to toxicity	Toxic epidermal				HLT:	HLGT:	<u>Pr</u> :		
	necrolysis		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec. : Infections and infestations		

			1	1	T		1	1	
Adverse Event Flushing  Grade 1: present N/A Grade 2: N/A Grade 3: N/A Grade 4: N/A Grade 5:  Attribution Code Unrelated Unlikely Possible Probable Definite	Flushing		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Hand-foot skin reaction  Grade 1: skin changes or dermatitis without pain (e.g., erythema, peeling) Grade 2: skin changes with pain, not interfering with function Grade 3: skin changes with pain, interfering with function N/A Grade 4: Grade 5: death related to toxicity	Hand-foot skin reaction	1, 2 or 3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Injection site				HLT:	HLGT:	<u>Pr</u> :		
	reaction		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec₁:		
					HLT:	HLGT:	<u>Pr</u> :	COO - DAIN	
	Injection site pain		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :	SSC <sub>1</sub> : PAIN	
					HLT:	HLGT:	Pr : General disorders and administration site conditions		
	Injection site itching		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> : Injury, poisoning and procedural complications		
					HLT:	HLGT:	Sec <sub>2</sub> : Skin and subcutaneous tissue disorders		
		1	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		_ <del></del>
Adverse Event Injection site reaction			<u>LL1</u> .	<u>111</u> •	HLT:	HLGT:	Sec <sub>1</sub> :		<u></u>
Grade 1: pain or itching or erythema Grade 2: pain or swelling, with inflammation or phlebitis Grade 3: ulceration or necrosis that is severe or prolonged, or requiring surgery	Injection site		шт	DT ·	HLT:	HLGT:	<u>Pr</u> :		_ <del></del>
Surgery  N/A Grade 4:  Grade 5: death related to toxicity	swelling	LL	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :		<u></u>
		2	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		_ <del></del>

_										
			2	LLI.	<u>F1</u> •	HLT:	HLGT:	Sec₁:		
						HLT:	HLGT:	<u>Pr</u> :		
		Injection site phlebitis		LLT:	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :		
						HLT:	HLGT:	Sec <sub>2</sub> : Vascular disorders		
			3		P.T	HLT:	HLGT:	<u>Pr</u> :		
			3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec₁:		
		Injection site		LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		
		necrosis		<u>LLI</u> :	<u>F1</u> :	HLT:	HLGT:	Sec <sub>1</sub> :		
	Adverse Event Nail changes	Nail changes		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		Nail discolouration	1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	N/A Grade 4: N/A Grade 5:		1 or 2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		Loss of nail(s)	2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Petechiae is graded in the HEMORRHAGE category.									
	Adverse Event Photosensitivity  Grade 1: painless erythema Grade 2: painful erythema Grade 3: erythema with desquamation N/A Grade 4: Grade 5: death related to toxicity	Photosensitivity		ш:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
/SKIN	Grade 1: localized pigmentation changes	Pigmentation changes (e.g., vitiligo)		<u>LLT</u> :	<u>PT</u> :	HLT:	disorders	Pr : Skin and subcutaneous tissue disorders		
TOLOGY/SKIN	Grade 2: generalized pigmentation changes N/A Grade 3: N/A Grade 4: N/A Grade 5:	Vitiliao		LLT:	PT:	HLT:	disorders	Pr : Skin and subcutaneous tissue disorders		

ا ⊻ٍ		viuligo		<u></u> .	<u>r.</u> .					I	1
: DERM						<u>HLT</u> :	HLGT : Autoimmune disorders	Sec. : Immune system disorders			
Category: DERMA	Adverse Event Pruritus  Grade 1: mild or localized, relieved spontaneously or by local measures Grade 2: intense or widespread, relieved spontaneously or by systemic measures Grade 3: intense or widespread and poorly controlled despite treatment NA Grade 4: Grade 5: death related to toxicity	Pruritus	1, 2 or 3	<u>LLT</u> : Pruritis	PT: Pruritus NOS	<u>HLT</u> : Pruritus NEC	HLGT: Epidermal and dermal conditions	Pr : Skin and subcutaneous tissue disorders	<u>SSC.</u> : ANAPHYLAXI S		
	Purpura is graded in the HEMORRHAGE category										
	Adverse Event Radiation dermatitis  Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema Grade 3: confluent moist desquamation >= 1.5 cm diameter and not confined to skin folds; pitting edema	Radiation		LLT:	PT:	HLT:	HLGT:	Pr:	SSC <sub>1</sub> :		
	Grade 4: skin necrosis or ulceration of full thickness dermis; may include bleeding not induced by minor trauma or abrasion Grade 5: death related to toxicity  Note: Pain associated with radiation dermatitis is graded separately in the PAIN category as Pain due to radiation.	dermatitis				<u>HLT</u> :	HLGT:	<u>Sec.</u> :			
	Adverse Event Radiation recall reaction (reaction following chemotherapy in the absence of additional radiation therapy that occurs in a previous radiation port)  Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema Grade 3: confluent moist desquamation >= 1.5 cm diameter and not confined to skin folds; pitting edema Grade 4: skin necrosis or ulceration of full thickness dermis; may include bleeding not induced by minor trauma or abrasion Grade 5: death related to toxicity	Radiation recall reaction		шт	<u>PT</u> :	<b>HLT</b> :	HLGT:	<u>Pr</u> :			
		Rash/desquamati on		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			

	Rash macular		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Rash/desquamation		1, 2 or 3	LLT:	PT:	HLT:	HLGT : Epidermal and	Pr : Skin and subcutaneous tissue		
Grade 1: macular or papular eruption or erythema without associated symptoms Grade 2: macular or papular eruption or erythema with pruritus or other		1, 2 or 3	<u>LLT</u> :			dermal conditions	disorders		
associated symptoms covering <50% of body surface or localized desquamation or other lesions covering <50% of body surface area Grade 3: symptomatic generalized crythroderma or macular, papular or vesicular eruption or desquamation covering >=50% of body surface area Grade 4: generalized exfoliative dermatitis or ulcerative dermatitis	Eruption		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Grade 5: death related to toxicity  Note: Stevens-Johnson syndrome is graded separately as Erythema multiforme in the DERMATOLOGY/SKIN category. Also consider Allergic	Rash erythematous	1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
reaction/hypersensitivity.		3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Dermatitis exfoliative	4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Rash/dermatitis associated with high-dose chemotherapy or BMT studies.  Grade 1: faint erythema or dry desquamation Grade 2: moderate to brisk erythema or a patchy moist desquamation, mostly confined to skin folds and creases; moderate edema Grade 3: confluent moist desquamation >1.5 cm diameter and not confined to skin folds; pitting edema Grade 4: skin necrosis or ulceration of full thickness dermis; may include spontaneous bleeding not induced by minor trauma or abrasion N/A Grade 5:			LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		
	Rash/desquamati on		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Rash/desquamation associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.	Rash macular		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 1: macular or papular eruption or erythema covering <25% of body surface area without associated symptoms		1, 2 or 3	<u>LLT</u> :	PT:	HLT:	HLGT :	Pr:		

Grade 2: macular or papular eruption or erythema with pruritus or other associated symptoms covering >= 25 - <50% of body surface or localized desquamation or other lesions covering >=25 - <50% of body surface area	Papular skin eruption		LLT:	<u>F1</u> ·	<u>mer</u> .	negr .	다.		
Grade 3: symptomatic generalized erythroderma or symptomatic macular, papular or vesicular eruption, with bullous formation, or desquamation covering >=50% of body surface area  Grade 4: generalized exfoliative dermatitis or ulcerative dermatitis or bullous	Eruption		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
formation  Grade 5: death related to toxicity		1, 2 or 3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Note: Stevens-Johnson syndrome is graded separately as Erythema multiforme in the DERMATOLOGY/SKIN category. Also consider Allergic reaction/hypersensitivity.	Erythroderma		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Dermatitis exfoliative	4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Urticaria (hives, welts, wheals)	Urticaria (hives, welts, wheals)	1, 2 or 3	LLT:			<u>HLGT</u> :	<u>Pr</u> :		
Grade 1: requiring no medication Grade 2: requiring PO or topical treatment or IV medication or steroids for		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT : Allergic conditions	Sec. : Immune system	SSC.:: ANAPHYLAXI S	
<24 hours <u>Grade 3</u> : requiring IV medication or steroids for >=24 hours <u>N/A Grade 4</u> :		1, 2 or 3	<u>LLT</u> :				disorders		
Grade 5: death related to toxicity	Wheals	1, 2 or 3	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		
					_	HLGT:	Sec₁:		_
	Wound-infectious	1, 2, 3 or	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Wound-infectious		4			_	HLGT:	Sec₁:		
Grade 1: cellulitis Grade 2: superficial infection Grade 3: infection requiring IV antibiotics	Cellulitis	1	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 4: necrotizing fasciitis Grade 5: death related to toxicity						HLGT:	Sec₁:		
		4	LLT:	<u>PT</u> :	HLT : Muscle and soft tissue infections	HLGT:	<u>Pr</u> :		
			-		HLT:	HLGT : Musculoskeletal and connective tissue disorders NEC	<u>Sec</u> <sub>1</sub> :		

Adverse Event Wound-non-infectious  Grade 1: incisional separation Grade 2: incisional hernia Grade 3: fascial disruption without evisceration Grade 4: fascial disruption with evisceration Grade 5: death related to toxicity	Wound-non- infectious		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :			
Adverse Event Dermatology/Skin-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
				ENDO	RINE					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae)  N/A Grade 1: Grade 2: present N/A Grade 3:	Cushingoid appearance (e.g., moon face, buffalo hump, centripetal obesity, cutaneous striae)	2	<u>LLT</u> :		<u>HLT</u> :	HLGT:	Pr:			
N/A Grade 4: N/A Grade 5: Note: Also consider Hyperglycemia, Hypokalemia		2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
			-		<u>HLT</u> :	HLGT:	<u>Sec.</u> :			
Adverse Event Feminization of male  N/A Grade 1: N/A Grade 2:	Feminization of	3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 3: present N/A Grade 4: Grade 5: death related to toxicity	male				<u>HLT</u> :	<u>HLGT</u> :	Sec <sub>1</sub> :			
Adverse Event Gynecomastia					HLT:	HLGT:	<u>Pr</u> :			

	Grade 1: mild Grade 2: pronounced or painful Grade 3: pronounced or painful and requiring surgery NA Grade 4: Grade 5: death related to toxicity	Gynecomastia	1, 2 or 3	LLT: Gynecomastia	PT: Gynaecomast ia	<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
	Adverse Event Hot flashes/flushes	Hot flashes		<u>LLT</u> :						
	Grade 1: mild or no more than 1 per day Grade 2: moderate and greater than 1 per day N/A Grade 3: N/A Grade 4: N/A Grade 5:	Hot flushes		LLT:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
Category: ENDOCRINE			1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
gory:		Hypothyroidism		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Cate	Adverse Event Hypothyroidism  Grade 1: asymptomatic, TSH elevated, no therapy given	Trypouryroidisin		<u>LL1</u> .		HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
	Grade 2: symptomatic or thyroid replacement treatment given Grade 3: patient hospitalized for manifestations of hypothyroidism Grade 4: myxedema coma		1	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Grade 5: death related to toxicity	Myxedema	4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		iwyxedema	7	<u></u> .	<u></u>	HLT:	HLGT:	<u>Sec₁</u> :		
	Adverse Event Masculinization of female  N/A Grade 1:  N/A Grade 2:  Grade 3: present	Masculinization of	3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	N/A Grade 4: Grade 5: death related to toxicity	female				<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
	Adverse Event SIADH (syndrome of inappropriate antidiuretic hormone)  N/A Grade 1:  N/A Grade 2:  Grade 3: present	SIADH (syndrome of inappropriate		LLT:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
	N/A Grade 4: Grade 5: death related to toxicity	antidiuretic hormone)				<u>HLT</u> :	HLGT:	<u>Sec</u> 1:		

Adverse Event Endocrine-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
			GAS	STROIN	TESTINAL					
Toxicity category and code name	Description (reported term)	Grade	LL I	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Amylase is graded in the METABOLIC/LABORATORY category										
Adverse Event Anorexia  Grade 1: loss of appetite Grade 2: oral intake significantly decreased	Anorexia	1, 2, 3 or 4	LLT:							
Grade 3: requiring IV fluids Grade 4: requiring feeding tube or parenteral nutrition Grade 5: death related to toxicity		1	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Ascites (non-malignant)					HLT:	HLGT:	<u>Pr</u> :			
Grade 1: asymptomatic, Grade 2: symptomatic, requiring diuretics Grade 3: symptomatic, requiring therapeutic paracentesis Grade 4: life-threatening physiologic consequences	Ascites (non- malignant)	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :			
Grade 5: death related to toxicity					HLT:	HLGT:	<u>Sec₂</u> :			

Adverse Event Colitis  N/A Grade 1: Grade 2: abdominal pain with mucus and/or blood in stool Grade 3: abdominal pain, fever, change in bowel habits with ileus or peritoneal signs, and radiographic or biopsy documentation Grade 4: perforation or requiring surgery or toxic megacolon Grade 5: death related to toxicity	Colitis		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Melena/GI bleeding, Rectal bleeding/hematochezia, Hypotension.									
Adverse Event Constipation  Grade 1: requiring stool softener or dietary modification Grade 2: requiring laxatives Grade 3: obstipation requiring manual evacuation or enema Grade 4: obstruction or toxic megacolon Grade 5: death related to toxicity	Constipation	1, 2, 3 or 4	<u>LLT</u> :	PT:	<u>HLT</u> :	HLGT:	Pr:		
Adverse Event Dehydration  Grade 1: dry mucous membranes and/or diminished skin turgor Grade 2: requiring IV fluid replacement (brief) Grade 3: requiring IV fluid replacement (sustained) Grade 4: physiologic consequences requiring intensive care; or	Dehydration	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
hemodynamic collapse <u>Grade 5</u> : death related to toxicity  Note: Also consider Diarrhea, Vomiting, Stomatitis/pharyngitis (oral/pharyngeal mucositis), Hypotension.		1	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		

Adverse Event Diarrhea patients without colostomy  Grade 1: increase of <4 stools/day over pre-treatment Grade 2: increase of 4-6 stools/day, or nocturnal stools Grade 3: increase of >= 7 stools/day or incontinence; or need for parenteral support for dehydration Grade 4: physiologic consequences requiring intensive care; or hemodynamic collapse Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain, Dehydration, Hypotension.	Diarrhea patients without colostomy	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>타</u> ::		
	Diarrhea patients with a colostomy		LLT:	<u>PT</u> :		HLGT:	Pr:		
Adverse Event Diarrhea associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.			<u>LLT</u> :	<u>PT</u> :		HLGT:	<u>Pr</u> :		
Grade 1: > 500 - <= 1000 mL of diarrhea/day Grade 2: > 1000 - <=1500 mL of diarrhea/day Grade 3: > 1500 mL of diarrhea/day Grade 4: severe abdominal pain with or without ileus Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4	Diarrhea associated with graft versus host disease (GVHD)	1, 2, 3 or 4		PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC1: SECONDARY	
Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain, Dehydration, Hypotension.			<u></u> :	<u>F1</u> :	HLT:	HLGT:		PROMISED STATE	

Adverse Event Diarrhea for pediatric BMT studies, if specified in the protocol.  Grade 1: >5 - <=10 mL/kg of diarrhea/day Grade 2: >10 - <= 15 mL/kg of diarrhea/day Grade 3: >15 mL/kg of diarrhea/day N/A Grade 4: Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Pain, Dehydration, Hypotension.	Diarrhea	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>ньст</u> :	<u>Pr</u> :		
Adverse Event Duodenal ulcer (requires radiographic or endoscopic documentation)  N/A Grade 1: Grade 2: requiring medical management or non-surgical treatment Grade 3: uncontrolled by outpatient medical management; requiring hospitalization Grade 4: perforation or bleeding, requiring emergency surgery Grade 5: death related to toxicity	Duodenal ulcer	2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :	<u>SSC.</u> :	
Adverse Event Dyspepsia/heartburn  Grade 1: mild Grade 2: moderate Grade 3: severe N/A Grade 4: N/A Grade 5:	Dyspepsia/heartb urn	1, 2 or 3		<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Dysphagia, esophagitis, odynophagia (painful swallowing)  Grade 1: mild dysphagia, but can eat regular diet Grade 2: dysphagia, requiring predominantly pureed, soft, or liquid diet Grade 3: dysphagia, requiring IV hydration Grade 4: complete obstruction (cannot swallow saliva) requiring enteral or	Dysphagia	1, 2, 3 or 4 1, 2, 3 or 4	<u>LLT</u> :			HLGT:	Pr:		
parenteral nutritional support, or perforation  Grade 5: death related to toxicity  Note: If the adverse event is radiation-related, grade either under  Dysphagia-esophageal related to radiation or Dysphagia-pharyngeal  related to radiation.	Odynophagia	1, 2, 3 or 4	<u>LLT</u> :	- <u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		

Adverse Event Dysphagia-esophageal related to radiation  Grade 1: mild dysphagia, but can eat regular diet  Grade 2: dysphagia, requiring predominantly pureed, soft, or liquid diet.  Grade 3: dysphagia, requiring feeding tube, IV hydration, or hyperalimentation	Dysphagia- esophageal	1, 2, 3 or		<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Grade 4: complete obstruction (cannot swallow saliva); ulceration with bleeding not induced by minor trauma or abrasion or perforation Grade 5: death related to toxicity  Note: Fistula is graded separately as Fistula-esophageal. Also consider Pain due to radiation, Mucositis due to radiation.	related to radiation	4	<u>LLT</u> :		<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
Adverse Event Dysphagia-pharyngeal related to radiation  Grade 1: mild dysphagia, but can eat regular diet  Grade 2: dysphagia, requiring predominantly pureed, soft, or liquid diet.  Grade 3: dysphagia, requiring feeding tube, IV hydration, or hyperalimentation  Grade 4: complete obstruction (cannot swallow saliva); ulceration with bleeding not induced by minor trauma or abrasion or perforation  Grade 5: death related to toxicity  Note: Fistula is graded separately as Fistula-esophageal. Also consider Pain due to radiation, Mucositis due to radiation.	Dysphagia- pharyngeal related to radiation	1, 2, 3 or 4	<u>LLT</u> :	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> ::		
Adverse Event Fistula-esophageal  N/A Grade 1: N/A Grade 2:	Fistula-	3 or 4	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		
Grade 2: present Grade 4: requiring surgery Grade 5: death related to toxicity	esophageal	3 01 4	<u>uu :</u>	<u>rr</u> :	HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
Adverse Event Fistula-intestinal  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: requiring surgery Grade 5: death related to toxicity	Fistula-intestinal	3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		

		Fistula- Pharyngeal		шт:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Fistula-rectal/anal  N/A Grade 1: N/A Grade 2:		3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Grade 3: present Grade 4: requiring surgery Grade 5: death related to toxicity		3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
GASTROINTESTINAL	Adverse Event Flatulence  Grade 1: mild Grade 2: moderate N/A Grade 3: N/A Grade 4: N/A Grade 5:	Flatulence	1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Category:	Adverse Event Gastric ulcer (requires radiographic or endoscopic documentation)  N/A Grade 1: Grade 2: requiring medical management or non-surgical treatment Grade 3: bleeding without perforation, uncontrolled by outpatient medical management; requiring hospitalization or surgery Grade 4: perforation or bleeding, requiring emergency surgery Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia  Attribution Code Unrelated Unlikely Possible Probable Definite	Gastric ulcer	2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : UPPER GI BLEEDING/PE RFORATION	

Adverse Event Gastritis  N/A Grade 1: Grade 2: requiring medical management or non-surgical treatment Grade 3: uncontrolled by out-patient medical management; requiring hospitalization or surgery Grade 4: life-threatening bleeding, requiring emergency surgery Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia	Gastritis	2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Hematemesis is graded in the HEMORRHAGE category									
Hematochezia is graded in the HEMORRHAGE category as Rectal bleeding/hematochezia									
Adverse Event Ileus (or neuroconstipation)  N/A Grade 1: Grade 2: intermittent, not requiring intervention Grade 3: requiring non-surgical intervention Grade 4: requiring surgery Grade 5: death related to toxicity	lleus (or neuroconstipation )	2, 3 or 4	ш:	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		
Adverse Event mouth dryness  Grade 1: mild Grade 2: moderate N/A Grade 3: N/A Grade 4: N/A Grade 5:	Mouth dryness		ш:	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		
Note: Mucositis not due to radiation is graded in the GASTROINTESTINAL category for specific sites: Colitis, Esophagitis, Gastritis, Stomatitis/pharyngitis (oral/pharyngeal mucositis), and Typhlitis; or the RENAL/GENITOURINARY category for Vaginititis									

Adverse Event Mucositis due to radiation  Grade 1: erythema of the mucosa Grade 2: patchy pseudomembranous reaction (patches generally <= 1.5 cm in diameter and non-contiguous) Grade 3: confluent pseudomembranous reaction (contiguous patches generally > 1.5 cm in diameter) Grade 4: necrosis or deep ulceration; may include bleeding not induced by minor trauma or abrasion Grade 5: death related to toxicity  Note: Grade radiation mucositis of the larynx here. Dysphagia related to radiation is also graded as either Dysphagia-esophageal related to radiation or Dysphagia-pharyngeal related to radiation, depending on the site of treatment. Also consider Pain due to radiation.	Mucositis due to radiation	1, 2, 3 or 4	ш:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Nausea  Grade 1: able to eat Grade 2: oral intake significantly decreased Grade 3: no significant intake, requiring IV fluids N/A Grade 4: Grade 5: death related to toxicity  Attribution Code Unrelated Unlikely Possible Probable Definite	Nausea	1, 2 or 3	LLT : Nausea	<u>PT</u> : Nausea			Pr : Gastrointestinal disorders		
Adverse Event Pancreatitis  N/A Grade 1: N/A Grade 2: Grade 3: abdominal pain with pancreatic enzyme elevation Grade 4: complicated by shock (acute circulatory failure) Grade 5: death related to toxicity  Note: Amylase is graded in the METABOLIC/LABORATORY category. Also consider Hypotension.	Pancreatitis	3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr:		
Pharyngitis is graded in the GASTROINTESTINAL category as Stomatitis/pharyngitis (oral/pharyngeal mucositis									

Adverse Event Proctitis  Grade 1: increased stool frequency, occasional blood-streaked stools or rectal discomfort (including hemorrhoids) not requiring medication Grade 2: increased stool frequency, bleeding, mucus discharge, or rectal discomfort requiring medication; anal fissure Grade 3: increased stool frequency/diarrhea requiring parenteral support; rectal bleeding requiring transfusion; or persistent mucus discharge, necessitating pads Grade 4: perforation, bleeding or necrosis or other life-threatening complication requiring surgical intervention (e.g., colostomy) Grade 5: death related to toxicity  Note: Proctitis occurring more than 90 days after the start of radiation therapy is graded in the RTOG/EORTC Late Radiation Morbidity Scoring Scheme (See Appendix IV). Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Pain due to radiation. Fistula is graded separately as Fistula-rectal/anal.	Proctitis		<u>LT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:		
Adverse Event Salivary gland changes  Grade 1: slightly thickened saliva; may have slightly altered taste (e.g., metallic); additional fluids may be required  Grade 2: thick, ropy, sticky saliva; markedly altered taste; alteration in diet required  N/A Grade 3:  Grade 4: acute salivary gland necrosis  Grade 5: death related to toxicity	Salivary gland changes	1, 2 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	타:		
Adverse Event Sense of smell  Grade 1: slightly altered Grade 2: markedly altered N/A Grade 3: N/A Grade 4: N/A Grade 5:	Sense of smell	1 or 2	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Stomatitis/pharyngitis (oral/pharyngeal mucositis)  Grade 1: painless ulcers, erythema, or mild soreness in the absence of lesions	Stomatitis/pharyn gitis (oral/pharyngeal mucositis)	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 2: painful erythema, edema, or ulcers, but can eat or swallow Grade 3: painful erythema, edema, or ulcers requiring IV hydration Grade 4: severe ulceration or requires parenteral or enteral utritional support or prophylactic intubation Grade 5: death related to toxicity	Pharyngitis	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		

Í			1	1				-	1	
Note: Radiation-related mucositis is graded as Mucositis due to radiation.		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Stomatitis/pharyngitis (oral/pharyngeal mucositis) for BMT studies, if specified in the protocol.  Grade 1: painless ulcers, erythema, or mild soreness in the absence of	Stomatitis/pharyn gitis (oral/pharyngeal mucositis)	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
lesions  Grade 2: painful erythema, edema or ulcers but can swallow  Grade 3: painful erythema, edema, or ulcers preventing swallowing or requiring hydration or parenteral (or enteral) nutritional support  Grade 4: severe ulceration requiring prophylactic intubation or resulting in documented aspiration pneumonia  Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Note: Radiation-related mucositis is graded as Mucositis due to radiation.		1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Taste disturbance (dysgeusia)  Grade 1: slightly altered Grade 2: markedly altered	Taste disturbance	1 or 2	LLT:	PT :	HLT:	HLGT:	<u>Pr</u> :			
N/A Grade 3: N/A Grade 4: N/A Grade 5:	Dysgeusia	1 or 2	<u>LLT</u> :		<u>HLT</u> :	<u>HLGT</u> :	<u>Sec</u> <sub>1</sub> :			
Adverse Event Typhlitis (inflammation of cecum)  N/A Grade 1: N/A Grade 2: Grade 3: abdominal pain, diarrhea, fever, and radiographic or biopsy documentation Grade 4: perforation, bleeding or necrosis or other life-threatening		3 or 4	<u>LLT</u> :	PT :	HLT:	HLGT:	Pr:			
complication requiring surgical intervention (e.g., colostomy)  Grade 5: death related to toxicity  Note: Also consider Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia, Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia, Hypotension, Febrile neutropenia.	Inflammation of cecum		<u>LLT</u> :			::LST :				

Adverse Event Vomiting  Grade 1: 1 episode in 24 hours over pretreatment Grade 2: 2-5 episodes in 24 hours over pretreatment Grade 3: >= 6 episodes in 24 hours over pretreatment; or need for IV fluid: Grade 4: requiring parenteral nutrition; or physiologic consequences requiring intensive care; hemodynamic collapse Grade 5: death related to toxicity  Note: Also consider Dehydratiion.	Vomiting	1, 2, 3 or 4	<u>LLT</u> : Vomiting	PT: Vomiting	HLT : Nausea and vomiting symptoms	HLGT : Gastrointestinal signs and symptoms	Pr : Gastrointestinal disorders			
Weight gain is graded in the CONSTITUTIONAL SYMPTOMS category										
Weight loss is graded in the CONSTITUTIONAL SYMPTOMS category										
Adverse Event Gastrointestinal-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity			1	<b>HEMORI</b>	RHAGE					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	нцт	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Note: Transfusion in this section refers to pRBC infusion. For any bleeding with grade 3 or 4 platelets (< 50,000), always grade Hemorrhage/bleeding with grade 3 or 4 thrombocytopenia. Also consider Platelets, Transfusion: pRBCs, and Transfusion: Platelets in addition to grading severity by grading the site or type of bleeding. If the site or type of Hemorrhage/bleeding is listed, also use the grading that incorporates the site of bleeding: CNS Hemorrhage/bleeding with surgery, Melena/Gl bleeding, Petechiae/purpura (Hemorrhage/bleeding into skin), Rectal bleeding/hematochezia, Vaginal bleeding. If the platelet count is >= 50,000 and the site or type of bleeding is listed, grade the specific site. If the site or type is not listed and the platelet count is >= 50,000, grade Hemorrhage/bleeding without grade 3 or 4 thrombocytopenia and specify the site or type in the OTHER category.										

Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity  Note: If the site is not listed, grade as Hemorrhage-Other (Specify site, ). This adverse event must be graded for any bleeding with grade 3 or 4 thrombocytopenia. Also consider Platelets, Hemoglobin,	Hemorrhage/blee ding with grade 3 or 4 thrombocytopeni a	1, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC.:	
Transfusion: platelets, Transfusion: pRBCs, site or type of bleeding.			LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>1</sub> :	
	Hemorrhage/blee ding without grade 3 or 4 thrombocytopeni a	1, 3 or 4	If you	need to set	a complete mapping version (C) please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76 Tel: +33 (0)6 73 51 or send an email to info@pf	madhoc Serres 88 17 37 96	3.0 - MedDRA),	<u>ssc.</u> :	
Adverse Event CNS hemorrhage/bleeding  N/A Grade 1: N/A Grade 2: Grade 3: bleeding noted on CT or other scan with no clinical consequences		3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :	<u>ssc.</u> :	
Grade 4: hemorrhagic stroke or hemorrhagic vascular event (CVA) with neurologic signs and symptoms Grade 5: death related to toxicity	ding		LLT: P		<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
Adverse Event Epistaxis  Grade 1: mild without transfusion  N/A Grade 2:	Epistaxis		LLT:	PT:	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :	SSC4:	

	Grade 3: requiring transfusion	<b>Ε</b> μισιαλίο	İ	<u></u> .	<u>F1</u> .		1		<u> </u>	i	ī
	Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity					<u>HLT</u> :	HLGT:	<u>Sec.</u> :			
	Adverse Event Hematemesis  Grade 1: mild without transfusion N/A Grade 2:	Hematemesis	1, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC1:	SSC <sub>2</sub> :	
	Grade 3: requiring transfusion Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity		,,,,,,,			<u>HLT</u> :	HLGT:	<u>Sec</u> 1 :			
Category: HEMORRHAGE	Adverse Event Hematuria (in the absence of vaginal bleeding)  Grade 1: microscopic only  Grade 2: intermittent gross bleeding, no clots  Grade 3: persistent gross bleeding or clots; may require catheterization or instrumentation, or transfusion  Grade 4: open surgery or necrosis or deep bladder ulceration  Grade 5: death related to toxicity	Hematuria (in the absence of vaginal bleeding)	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>SSC.</u> :		
Ca	Adverse Event Hemoptysis					<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Grade 1: mild without transfusion  NA Grade 2:  Grade 3: requiring transfusion  Grade 4: catastrophic bleeding, requiring major non-elective intervention  Grade 5: death related to toxicity		1, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Sec₄</u> :	SSC₁:		
	State 3. death letated to toxicity					HLT : Haemorrhages NEC	HLGT : Vascular haemorrhagic disorders	Sec <sub>2</sub> : Vascular disorders			
	Adverse Event Hemorrhage/bleeding associated with surgery  Grade 1: mild without transfusion N/A Grade 2: Grade 3: requiring transfusion Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity  Note: Expected blood loss at the time of surgery is not graded as an adverse event.	Hemorrhage/blee ding associated with surgery	1, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			

Adverse Event Melena/GI bleeding	Melena/GI	1, 3 or 4	шт	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :	SSC <sub>2</sub> : UPPER GI BI FEDING/P	
Grade 1: mild without transfusion N/A Grade 2:	bleeding	1, 3 01 4	<u></u> .	<u></u>	HLT:	HLGT:	Sec₁:	GE	ERFORATIO N	
Grade 3: requiring transfusion Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity		1, 3 or 4		PT:	HLT:	HLGT:	Pr : Gastrointestinal disorders	SSC1: HAEMORRHA		
		1, 3 01 4	<u>LL1</u> :	<u>F1</u> :	HLT:	HLGT:		GE		
	Petechiae/purpur				HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Petechiae/purpura (hemorrhage/bleeding into skin or mucosa)	a (hemorrhage/blee ding into skin or		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec₁:	SSC.:		
Grade 1: rare petechiae of skin Grade 2: petechiae or purpura in dependent areas of skin	mucosa)				HLT:	HLGT:	Sec₂:			
Grade 3: generalized petechiae or purpura of skin or petechiae of any mucosal site  N/A Grade 4:					HLT: Purpura and related conditions	HLGT : Skin vascular abnormalities	Pr : Skin and subcutaneous tissue disorders			
Grade 5: death related to toxicity	Purpura	1, 2 or 3	LLT : Purpura	PT : Purpura NOS	HLT : Purpuras (excl thrombocytopenic)	HLGT : Bleeding tendencies and purpuras (excl thrombocytopenic)		SSC <sub>1</sub> : HAEMORRHA GE		
					HLT : Bruising, ecchymosis and purpura	HLGT : Vascular haemorrhagic disorders	Sec <sub>2</sub> : Vascular disorders			
Adverse Event Rectal bleeding/hematochezia	Rectal				<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :		
Grade 1: mild without transfusion or medication Grade 2: persistent, requiring medication (e.g., steroid suppositories) and/or break from radiation treatment Grade 3: requiring transfusion Grade 4: catastrophic bleeding, requiring major non-elective intervention	bleeding/hematoc hezia		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Sec <sub>1</sub> :	<u>330,</u> .		
Grade 5: death related to toxicity	Hematochezia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Vaginal bleeding  Grade 1: spotting, requiring <2 pads per day  Grade 2: requiring >= 2 pads per day, but not requiring transfusion		1, 2, 3 or	LLT: Vaginal		HLT:	HLGT:	<u>Pr</u> :	<u>SSC.</u> :		
rado 3: requiring >= 2 pade per day, but not requiring transfusion	Vaginal bleeding	4	bleeding	haemorrhage	HLT : Reproductive system haemorrhages	HLGT : Vascular haemorrhagic disorders	Sec_1: Vascular disorders	HAEMORRHA GE		

Adverse Event Hemorrhage-Other (Specify,)  Grade 1: mild without transfusion N/A Grade 2: Grade 3: requiring transfusion Grade 4: catastrophic bleeding, requiring major non-elective intervention Grade 5: death related to toxicity										
				HEPA	ATIC					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred		HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Alkaline phosphatase  Grade 1: > ULN - 2.5 x ULN  Grade 2: > 2.5 - 5.0 x ULN  Grade 3: > 5.0 - 20.0 x ULN  Grade 4: > 20.0 x ULN  Grade 5: death related to toxicity	Alkaline phosphatase	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Bilirubin  Grade 1: > ULN - 1.5 x ULN Grade 2: > 1.5 - 3.0 x ULN Grade 3: > 3.0 - 10.0 x ULN Grade 4: > 10.0 x ULN Grade 5: death related to toxicity	Bilirubin	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 1: >= 2 - <3 mg/100 mL Grade 2: >= 3 - <6 mg/100 mL Grade 3: >= 6 - <15 mg/100 mL Grade 4: >= 15 mg/100 mL Grade 5: death related to toxicity	Bilirubin associated with graft versus host disease (GVHD)	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>1</sub> :		
					HLT:	HLGT:	<u>Sec₁</u> :			

	Adverse Event GGT (Gamma-Glutamyl transpeptidase)  Grade 1: > ULN - 2.5 x ULN Grade 2: > 2.5 - 5.0 x ULN Grade 3: > 5.0 - 20.0 x ULN Grade 4: > 20.0 x ULN Grade 5: death related to toxicity	GGT	1, 2, 3 or 4	<u>ut</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Hepatic enlargement  N/A Grade 1: N/A Grade 2: Grade 3: present N/A Grade 4: Grade 5: death related to toxicity  Note: Grade Hepatic enlargement only for treatment related adverse event including Veno-Occlusive Disease.	Hepatic enlargement	3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Category: HEPATIC	Adverse Event Hypoalbuminemia  Grade 1: < LLN - 3 g/dL Grade 2: >= 2 - <3 g/dL Grade 3: <2 g/dL N/A Grade 4: Grade 5: death related to toxicity	Hypoalbuminemi a	1, 2 or 3	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr : Sec <sub>1</sub> :		
Category		Liver dysfunction/failur	3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		<u> </u>	3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT : Movement disorders (incl Parkinsonism)	<u>Pr</u> :		
	Adverse Event Liver dysfunction/failure (clinical)					HLT:	HLGT : Hepatic and hepatobiliary disorders	Sec <sub>1</sub> : Hepatobiliary disorders		
	N/A Grade 1: N/A Grade 2: Grade 3: asterixis	Hepatic	4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Grade 4: encephalopathy or coma Grade 5: death related to toxicity	encephalopathy		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
			4	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		

		*	<u></u> .	<u>F1</u> -	HLT:	HLGT:	Sec <sub>1</sub> :		
Adverse Event Portal vein flow  N/A Grade 1:					HLT:	HLGT:	Pr:		
Grade 2: decreased portal vein flow Grade 3: reversalf/retrograde portal vein flow N/A Grade 4: Grade 5: death related to toxicity	Portal vein flow		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
Adverse Event SGOT (AST) (serum glutamic oxaloacetic transaminase)  Grade 1: > ULN - 2.5 x ULN Grade 2: > 2.5 - 5.0 x ULN	SGOT	1, 2, 3 or 4	<u>LLT</u> :	- <u>PT</u> :	HLT:	HLGT:	Pr:		
Grade 3: > 5.0 - 20.0 x ULN Grade 4: > 20.0 x ULN Grade 5: death related to toxicity		1, 2, 3 or 4	LLT:	<u></u> :	DLL:	nto1:	E:		
Adverse Event SGPT (ALT) (serum glutamic pyruvic transaminase)  Grade 1: > ULN - 2.5 x ULN  Grade 2: > 2.5 - 5.0 x ULN	SGPT	1, 2, 3 or 4	LLT:				Paris and the same of the same		
Grade 3: > 5.0 - 20.0 x ULN Grade 4: > 20.0 x ULN Grade 5: death related to toxicity	ALT	1, 2, 3 or 4	LLT:	<del>- PT</del> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Hepatic-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling									
Grade 5: death related to toxicity		INF	FCTION	l/FFBRII	LE NEUTROPENIA				

	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Adverse Event Catheter-related infection					HLT:	HLGT:	<u>Pr</u> : I			
	Grade 1: mild, no active treatment Grade 2: moderate, localized infection, requiring local or oral treatment Grade 3: severe, systemic infection, requiring IV antibiotic or antifungal treatment or hospitalization Grade 4: life-threatening sepsis (e.g., septic shock) Grade 5: death related to toxicity	Catheter-related infection	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec. : General disorders and administration site conditions			
	,					<u>HLT</u> :	HLGT:	Sec <sub>2</sub> : Injury, poisoning and procedural complications			
	Adverse Event Febrile neutropenia (fever of unknown origin without clinically or microbiologically documented infection) (ANC <1.0 x 10e9/L, fever >=38.5 degrees C)  N/A Grade 1: N/A Grade 2: Grade 3: present		3 or 4	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Grade 4: life-threatening sepsis (e.g., septic shock) Grade 5: death related to toxicity  Note: Hypothermia instead of fever may be associated with neutropenia and is graded here. Also consider Neutrophils.		3 01 4	:	<u>FI</u> :	HLT : Febrile disorders	HLGT:	Sec. : General disorders and administration site conditions			
UTROPENIA	Adverse Event Infection (documented clinically or microbiologically) with grade 3 or 4 neutropenia (ANC <1.0 x 10e9/L)  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: life-threatening sepsis (e.g., septic shock)	Infection with	2 or 4	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
ECTION/FEBRILE NEUTROPENIA	Grade 4: life-threatening sepsis (e.g., septic shock)  Grade 5: death related to toxicity  Note: Also consider Neutrophils. Hypothermia instead of fever may be associated with neutropenia and is graded here. In the absence of documented infection grade 3 or 4 neutropenia with fever is graded as Febrile neutropenia.	neutropenia	3 or 4	:	<u>F1</u> :	<u>HLT</u> :	HLGT:	Sec. :			

Category: INFE	Adverse Event Infection with unknown ANC  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: life-threatening sepsis (e.g., septic shock) Grade 5: death related to toxicity  Note: This adverse event criterion is used in the rare case when ANC is unknown.	Infection	3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :			
	Adverse Event Infection without neutropenia  Grade 1: mild, no active treatment Grade 2: moderate localized infection, requiring local or oral treatment Grade 3: severe, systemic infection, requiring IV antibiotic or antifungal treatment, or hospitalization Grade 4: lift-threatening sepsis (e.g., septic shock) Grade 5: death related to toxicity  Note: Also consider Neutrophils.	Infection without neutropenia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Wound-infectious is graded in the DERMATOLOGY/SKIN category										
	Adverse Event Infection/Febrile Neutropenia-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
					LYMPH	ATICS					
	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	нст	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Adverse Event Lymphatics	Lymphatics	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT : Lymphangiopathies	HLGT : Lymphatic noninfective disorders	Pr : Vascular disorders			

7: LYMPHATICS	Grade 1: mild lymphedema Grade 2: moderate lymphedema requiring compression; lymphocyst Grade 3: severe lymphedema limiting function; lymphocyst requiring surgery Grade 4: severe lymphedema limiting function with ulceration Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC.: OEDEMA		
	Adverse Event Lymphatics-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
				METAF		ADODATODY					
		T	1	WEIAE	OLIC/L	ABORATORY					
	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Adverse Event Acidosis (metabolic or respiratory)	Acidosis	1, 3 or 4	LLT : Acidosis	PT : Acidosis NOS	HLT : Metabolic acidoses (excl diabetic acidoses)	HLGT : Acid-base disorders	Pr: metabolism and nutrition disorders			
	<u>Grade 1</u> : pH < normal, but >= 7.3 N/A Grade 2:			LLT : Acidosis metabolic	PT: Metabolic acidosis NOS	HLT : Metabolic acidoses (excl diabetic acidoses)	HLGT : Acid-base disorders	Pr: metabolism and nutrition disorders			
	Grade 3: pH <7.3  Grade 5: death related to toxicity			LLT:	PT:	HLT : Conditions associated with abnormal gas exchange	HLGT : Respiratory disorders NEC	<u>Pr</u> : Respiratory, thoracic and mediastinal disorders			
	Grade 9. death related to toking			<u>LL1</u> .	<u>F1</u> .	HLT : Respiratory acidoses	HLGT : Acid-base disorders	Sec <sub>1</sub> : Metabolism and nutrition disorders			
	Adverse Event Alkalosis (metabolic or respiratory)		1, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Grade 1: pH > normal, but <= 7.5  N/A Grade 2:		1, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Grade 3: pH > 7.5  Grade 4: pH > 7.5 with life-threatening physiologic consequences  Grade 5: death related to toxicity			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
				<u> </u>		HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :			

Adverse Event Amylase  Grade 1: >ULN - 1.5 x ULN Grade 2: >1.5 - 2.0 x ULN Grade 3: >2.0 - 5.0 x ULN Grade 4: >5.0 x ULN Grade 5: death related to toxicity	Amylase	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Bicarbonate  Grade 1: < LLN - 16 mEq/dL Grade 2: 11 - 15 mEq/dL Grade 3: 8 - 10 mEq/dL Grade 4: <8 mEq/dL Grade 5: death related to toxicity	Bicarbonate	1, 2, 3 or 4	<u>ur</u> :	<u>PT</u> :	<u>НLТ</u> :	HLGT:	<u>Pr</u> :		
Adverse Event CPK (creatine phosphokinase)  Grade 1: >ULN - 2.5 x ULN Grade 2: > 2.5 - 5 x ULN Grade 3: > 5 - 10 x ULN Grade 4: > 10 x ULN Grade 5: death related to toxicity	СРК	1, 2, 3 or 4	<u>ur</u> :	<u>PT</u> :	<u>нгт</u> :	<u>HLGT</u> :	<u>Pr</u> :	<u>ssc.</u> :	
Adverse Event Hypercalcemia  Grade 1: >ULN - 11.5 mg/dL; >ULN - 2.9 mmol/L Grade 2: >11.5 - 12.5 mg/dL; >2.9 - 3.1 mmol/L	Hypercalcemia	1, 2, 3 or	шт	<b>PT</b> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 3: >12.5 - 13.5 mg/dL; >3.1 - 3.4 mmol/L Grade 4: > 13.5 mg/dL; >3.4 mmol/L Grade 5: death related to toxicity	, ротошоотна	4			HLT:	HLGT:	<u>Sec.</u> :		

Adverse Event Hypercholesterolemia  Grade 1: >ULN - 300 mg/dL; >ULN - 7.75 mmol/L Grade 2: >300 - 400 mg/dL; >7.75 - 10.34 mmol/L Grade 3: >400 - 500 mg/dL; >10.34 - 12.92 mmol/L Grade 4: >500 mg/dL; >12.92 mmol/L Grade 5: death related to toxicity	Hypercholesterol emia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Hyperglycemia  Grade 1: >ULN - 160 mg/dL; >ULN - 8.9 mmol/L Grade 2: >160 - 250 mg/dL; >8.9 - 13.9 mmol/L	Hyperglycemia	1, 2, 3 or	шт	PT:	HLT : Hyperglycaemic conditions	HLGT : Glucose metabolism disorders (incl	Pr : metabolism and nutrition disorders		
Grade 3: >250 - 500 mg/dL; >33.9 - 27.8 mmol/L Grade 4: >500 mg/dL; >27.8 mmol/L or acidosis Grade 5: death related to toxicity	турогууссина	4			NEC	diabetes mellitus)	Sec <sub>1</sub> : Endocrine disorders		
Adverse Event Hyperkalemia  Grade 1: >ULN - 5.5 mmol/L Grade 2: >5.5 - 6.0 mmol/L Grade 3: >6.0 - 7.0 mmol/L Grade 4: >7.0 mmol/L Grade 5: death related to toxicity	Hyperkalemia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>нгт</u> :	<u>HLGT</u> :	<u>Pr</u> :		
Adverse Event Hypermagnesemia  Grade 1: >ULN - 3.0 mg/dL; >ULN - 1.23 mmol/L N/A Grade 2: Grade 3: >3.0 - 8.0 mg/dL; >1.23 - 3.30 mmol/L Grade 4: >8.0 mg/dL; >3.30 mmol/L Grade 5: death related to toxicity	Hypermagnesemi a	1, 3 or 4	<u>LLT</u> :	PT:	HLT:	HLGT:	<u>Pr</u> :		

Category: METABOLIC/LABORA	Adverse Event Hypernatremia  Grade 1: >UNL - 150 mmol/L Grade 2: >150 - 155 mmol/L Grade 3: >155 - 160 mmol/L Grade 4: >160 mmol/L Grade 5: death related to toxicity	Hypernatremia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Categ	Adverse Event Hypertriglyceridemia  Grade 1: >UNL - 2.5 x ULN  Grade 2: >2.5 - 5.0 x ULN  Grade 3: >5.0 - 10 x ULN  Grade 4: >10 x ULN  Grade 5: death related to toxicity	Hypertriglyceride mia	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>н</u> LТ :	HLGT:	<u>Pr</u> :		
	Adverse Event Hyperuricemia  Grade 1: >ULN - <= 10 mg/dL; <= 0.59 mmol/L without physiologic consequences N/A Grade 2: Grade 3: >ULN - 10 mg/dL; <= 0.59 mmol/L with physiologic consequences Grade 4: >10 mg/dL; >0.59 mmol/L Grade 5: death related to toxicity  Note: Also consider Tumor lysis syndrome, Renal failure, Creatinine, Hyperkalemia.	Hyperuricemia	1, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Hypocalcemia  Grade 1: < LLN - 8.0 mg/dL; < LLN - 2.0 mmol/L  Grade 2: 7.0 - <8.0 mg/dL; 1.75 - <2.0 mmol/L  Grade 3: 6.0 - <7.0 mg/dL; 1.5 - <1.75 mmol/L  Grade 4: <6.0 mg/dL; <1.5 mmol/L  Grade 5: death related to toxicity	Hypocalcemia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<b>HLT</b> :	HLGT:	Pr:		

Adverse Event Hypoglycemia  Grade 1: < LLN - 55 mg/dL; < LLN - 3.0 mmol/L Grade 2: 40 - <55 mg/dL; 2.2 - <3.0 mmol/L Grade 3: 30 - <40 mg/dL; 1.7 - 2.2 mmol/L Grade 4: <30 mg/dL; <1.7 mmol/L Grade 5: death related to toxicity		1, 2, 3 or 4	шт:	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		
Adverse Event Hypokalemia  Grade 1: < LLN - 3.0 mmol/L  N/A Grade 2:  Grade 3: 2.5 - <3.0 mmol/L  Grade 4: <2.5 mmol/L	Hypokalemia	1, 3 or 4	LLT:	PI:	HLT:	HLGT:	<u>Sec.</u> : <u>Pr</u> :		
Grade 5: death related to toxicity  Adverse Event Hypomagnesemia  Grade 1: < LLN - 1.2 mg/dL; < LLN - 0.5 mmol/L  Grade 2: 0.9 - <1.2 mg/dL; 0.4 - <0.5 mmol/L  Grade 3: 0.7 - <0.9 mg/dL; 0.3 - <0.4 mmol/L	Hypomagnesemi a	1, 2, 3 or 4	шт	<u>PT</u> :	HLT:	HLGT:	Pr:		
Grade 4: <0.7 mg/dL; <0.3 mmol/L Grade 5: death related to toxicity  Adverse Event Hyponatremia Grade 1: < LLN - 130 mmol/L N/A Grade 2: Grade 3: 120 - <130 mmol/L	Hyponatremia	1, 3 or 4	шт:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 4: <120 mmol/L Grade 5: death related to toxicity  Adverse Event Hypophosphatemia  Grade 1: < LLN - 2.5 mg/dL; < LLN - 0.8 mmol/L Grade 2: >=2.0 - <2.5 mg/dL; >=0.6 - <0.8 mmol/L	Hypophosphatem ia	1, 2, 3 or 4	шт:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 3: >=1.0 - <2.0 mg/dL; >=0.3 - <0.6 mmol/L Grade 4: <1.0 mg/dL; <0.3 mmol/L Grade 5: death related to toxicity									

Hypothyroidism is graded in the ENDOCRINE category										
Adverse Event Lipase  Grade 1: >ULN - 1.5 x ULN Grade 2: >1.5 - 2.0 x ULN Grade 3: >2.0 - 5.0 x ULN Grade 4: >5.0 x ULN Grade 5: death related to toxicity	Lipase	1, 2, 3 or 4	шт:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Metabolic/Laboratory-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening of disabling Grade 5: death related to toxicity										
			MUS	SCULOS	SKELETAL					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Arthralgia is graded in the PAIN category										
Adverse Event Arthritis	Arthritis	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 1: mild pain with inflammation, erythema or joint swelling but not interfering with function		1, 2, 3 or 4 1, 2, 3 or 4		<u>PT</u> :	HLT:	HLGT:	Pr:			
Grade 1: mild pain with inflammation, erythema or joint swelling but not interfering with function Grade 2: moderate pain with inflammation, erythema, or joint swelling interfering with function, but not interfering with activities of daily living Grade 3: severe pain with inflammation, erythema, or joint swelling and interfering with activities of daily living Grade 4: disabling			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr :			
Grade 1: mild pain with inflammation, erythema or joint swelling but not interfering with function Grade 2: moderate pain with inflammation, erythema, or joint swelling interfering with function, but not interfering with activities of daily living Grade 3: severe pain with inflammation, erythema, or joint swelling and interfering with activities of daily living		1, 2, 3 or 4 1, 2, 3 or 4	<u>LLT</u> :							

	factivities of daily living	Ininscie meaviless	-	<u> </u>	<u>  F.L.</u> -					
	Grade 3: symptomatic and interfering with activities of daily living Grade 4: bedridden or disabling Grade 5: death related to toxicity		4			HLT : Neuromuscular disorders NEC	HLGT : Neuromuscular disorders	Sec. : Nervous system disorders		
TAL	Adverse Event Myositis (inflammation/damage of muscle)  Grade 1: mild pain, not interfering with function	Myositis	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:		
OSKELE	Grade 2: pain interfering with function, but not interfering with activities of daily living Grade 3: pain interfering with function and interfering with activities of daily living			<u>LLT</u> :				<u>.</u>		
Category: MUSCULOSKELETAL	Grade 4: bedridden or disabling Grade 5: death related to toxicity  Note: Myositis implies muscle damage (i.e., elevated CPK). Also consider CPK.		1, 2, 3 or	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
ategory:			4			HLT:	HLGT:	Sec <sub>1</sub> :		
O	Myalgia is graded in the PAIN category									
	Adverse Event Osteonecrosis (avascular necrosis)  Grade 1: asymptomatic and detected by imaging only Grade 2: symptomatic and interfering with function, but not interfering with	Osteonecrosis	1, 2, 3 or 4	<u>ur</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	activities of daily living  Grade 3: symptomatic and interfering with activities of daily living  Grade 4: symptomatic; or disabling  Grade 5: death related to toxicity		1, 2, 3 or 4	<u></u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Musculoskeletal-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity									
					NEURO	LOGY				

			I		1		Pr = Primary SOC	1		
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Sec <sub>n</sub> = Secondary	SSC1	SSC2	SSC3
Aphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category										
Adverse Event Arachnoiditis/meningismus/radiculitis	Arachnoiditis/men		LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Grade 1: mild pain not interfering with function Grade 2: moderate pain interfering with function, but not interfering with activities of daily living Grade 3: severe pain interfering with activities of daily living	s			<u> </u>	<u>HLT</u> :	HLGT:	<u>Sec.</u> :			
Grade 4: unable to function or perform activities of daily living; bedridden; paraplegia Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Note: Also consider Headache, Vomiting, Fever.	Radiculitis		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Ataxia (incoordination)  Grade 1: asymptomatic but abnormal on physical exam, and not interfering	Ataxia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
with function  Grade 2: mild symptoms interfering with function, but not interfering with activities of daily living  Grade 3: moderate symptoms interfering with activities of daily living  Grade 4: bedridden or disabling  Grade 5: death related to toxicity		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event CNS cerebrovascular ischemia	CNS cerebrovascular		LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
N/A Grade 1: N/A Grade 2:	ischemia				HLT:	HLGT:	Sec₁:			
Grade 3: transient ischemic event or attack (TIA) Grade 4: permanent event (e.g., cerebral vascular accident) Grade 5: death related to toxicity		3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
					HLT:	HLGT:	Sec₁:			
CNS hemorrhage/bleeding is graded in the HEMORRHAGE category										
Adverse Event Cognitive disturbance/learning problems (for pediatrics)  Grade 1: cognitive disability; not interfering with work/school performance;	Cognitive	1, 2, 3 or	117.	DT.	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
preservation of intelligence <u>Grade 2</u> : cognitive disability; interfering with work/school performance; decline of 1 SD (Standard Deviation) or loss of developmental milestones <u>Grade 3</u> : cognitive disability; resulting in significant impairment of work/school performance; cognitive decline > 2 SD	disturbance/learni ng problems	4	<u>LL1</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :			

10 1 4 1 199 4 1 1 4 1 4 1 6					1	1	1		
Grade 4: inability to work/frank mental retardation Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Confusion	1, 2, 3 or	IIT:	PT:	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Confusion	Contusion	4	<u></u> .	<u>F1</u> .	HLT:	HLGT:	Sec₁:		
Grade 2: confusion or disorientation or attention deficit interfering with	Disorientation		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
function, but not interfering with activities of daily living  Grade 3: confusion or delirium interfering with activities of daily living  Grade 4: harmful to others or self; requiring hospitalization		1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 5: death related to toxicity		1012	<u>LL1</u> .	<u></u> .	HLT:	HLGT:	Sec₁:		
	Delirium	3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Cranial neuropathy is graded in the NEUROLOGY category as Neuropathy-cranial									
Adverse Event Delusions  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: toxic psychosis Grade 5: death related to toxicity	Delusions	3 or 4	ш:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Somnolence	1 or 2	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Depressed level of consciousness		. 0. 2		<u></u> .	<u>HLT</u> :	<u>HLGT</u> :	Sec <sub>1</sub> :		
Grade 1: somnolence or sedation not interfering with function Grade 2: somnolence or sedation interfering with function, but not interfering with activities of daily living Grade 3: obtundation or stupor; difficult to arouse; interfering with activities		1 or 2	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Obtundation	3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Note: Syncope (fainting) is graded in the NEUROLOGY category.	L	l		1	L	1			

	Stupor		<u>LLT</u> :	<u>PT</u> :	HLT:	<u>HLGT</u> :	<u>Pr</u> :		
		3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Coma		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Dizziness/lightheadedness  Grade 1: not interfering with function Grade 2: interfering with function, but not interfering with activities of daily living	Dizziness/lighthe adedness	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT : Neurological	Pr : Nervous system		
Grade 3: interfering with activities of daily living Grade 4: bedridden or disabling Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :			disorders NEC	disorders		
Dysphasia, receptive and/or expressive, is graded under Speech impairment in the NEUROLOGY category									
	Extrapyramidal/in voluntary movement/restles sness	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 1: mild involuntary movements not interfering with function Grade 2: moderate involuntary movements interfering with function, but not interfering with activities of daily living		1, 2, 3 or	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 3: severe involuntary movements or torticollis interfering with activities of daily living Grade 4: bedridden or disabling Grade 5: death related to toxicity		4			HLT:	HLGT:	Sec. :		
		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Hallucinations  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: toxic psychosis Grade 5: death related to toxicity	Hallucinations	3 or 4	<u> ШТ</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Headache is graded in the PAIN category									

	Adverse Event Insomnia  Grade 1: occasional difficulty sleeping not interfering with function Grade 2: difficulty sleeping interfering with function, but not interfering with activities of daily living Grade 3: frequent difficulty sleeping, interfering with activities of daily living N/A Grade 4: Grade 5: death related to toxicity	Insomnia	1, 2 or 3	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr:		
	Note: This adverse event is graded when insomnia is related to treatment. If pain or other symptoms interfere with sleep do NOT grade as insomnia.	Difficulty sleeping		<u>LLT</u> :		<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
	Adverse Event Irritability (children <3 years of age)  Grade 1: mild; easily consolable  Grade 2: moderate; requiring increased attention  Grade 3: severe; inconsolable  NA Grade 4:  Grade 5: death related to toxicity	Irritability	1, 2 or 3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Adverse Event Leukoencephalopathy associated with radiological findings  Grade 1: mild increase in SAS (subarachnoid space) and/or mild ventriculomegaly; and/or small (+/- multiple) focal T2 hyperintensities, involving periventricular white matter or <1/3 of susceptible areas of cerebrum  Grade 2: moderate increase in SAS; and/or moderate ventriculomegaly; and/or focal T2 hyperintensities extending into centrum ovale; or involving 1/3 to 2/3 of susceptible areas of cerebrum  Grade 3: severe increase in SAS; severe ventriculomegaly; near total white matter T2 hyperintensities or diffuse low attenuation (CT); focal white matter necrosis (cystic)  Grade 4: severe increase in SAS; severe ventriculomegaly; diffuse low attenuation with calcification (CT); diffuse white matter necrosis (MRI)  Grade 5: death related to toxicity	Leukoencephalop athy	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:		
Category: NEUROLOGY	Adverse Event Memory loss  Grade 1: memory loss not interfering with function	Memory loss	1, 2, 3 or 4	LLT : Memory loss	PT : Memory impairment	HLT:		<u>Pr</u> :		
EUF	Grade 2: memory loss interfering with function, but not interfering with					<u>HLT</u> :	HLGT:	<u>Sec₁</u> :		
gory: N	activities of daily living <u>Grade 3</u> : memory loss interfering with activities of daily living <u>Grade 4</u> : amnesia <u>Grade 5</u> : death related to toxicity		4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Sate						HLT:	HLGT:	Sec₁:		
)	Adverse Event Mood alteration-anxiety, agitation	Mood alteration- anxiety, agitation	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		

Grade 1: mild mood alteration not interfering with function Grade 2: moderate mood alteration interfering with function, but not interfering with activities of daily living		1, 2, 3 or	IIIT :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 3: severe mood alteration interfering with activities of daily living Grade 4: suicidal ideation or danger to self Grade 5: death related to toxicity		4	<u></u> .	<u></u>	HLT:	HLGT:	Sec <sub>1</sub> :		
State of the state		4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Mood alteration-depression  Grade 1: mild mood alteration not interfering with function Grade 2: moderate mood alteration interfering with function, but not interfering with activities of daily living	Mood alteration- depression	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Grade 3: severe mood alteration interfering with activities of daily living Grade 4: suicidal ideation or danger to self Grade 5: death related to toxicity		4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Mood alteration-euphoria  Grade 1: mild mood alteration not interfering with function Grade 2: moderate mood alteration interfering with function, but not interfering with activities of daily living Grade 3: severe mood alteration interfering with activities of daily living Grade 4: danger to self Grade 5: death related to toxicity	Mood alteration- euphoria	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:		
Neuropathic pain is graded in the PAIN category.									
Adverse Event Neuropathy - cranial  N/A Grade 1: Grade 2: present, not interfering with activities of daily living Grade 3: present, interfering with activities of daily living Grade 4: life-threatening, disabling Grade 5: death related to toxicity  Attribution Code Unrelated Unlikely Possible Probable Definite	Neuropathy - cranial	2, 3 or 4	LLT:	PI:	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Neuropathy - motor  Grade 1: subjective weakness but no objective findings Grade 2: mild objective weakness interfering with function, but not Interfering with activities of daily living	Neuropathy - motor	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		

Grade 3: objective weakness interfering with activities of daily living Grade 4: paralysis Grade 5: death related to toxicity		4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Neuropathy-sensory	Neuropathy- sensory	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 1: loss of deep tendon reflexes or paresthesia (including tingling) but not interfering with function Grade 2: objective sensory loss or paresthesia (including tingling),	Loss of deep tendon reflexes	1	LLT:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
interfering with function, but not interfering with activities of daily living <a href="Grade">Grade 3</a> : sensory loss or paresthesia interfering with activities of daily living <a href="Grade 4">Grade 4</a> : permanent sensory loss that interferes with function <a href="Grade 5">Grade 5</a> : death related to toxicity	Paresthesia		LLT:	PT:	HLT:	HLGT:	Pr:		
		1 or 2	<u>LLT</u> :	<u> </u>	<u> </u>	ileor .	<u></u> .		
Adverse Event Nystagmus  Grade 1: present N/A Grade 2: N/A Grade 3: N/A Grade 4: N/A Grade 5: Note: Also consider Vision-double vision.	Nystagmus	1	шт:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Personality/behavioral  Grade 1: change, but not disruptive to patient or family	Personality/beha	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 2: disruptive to patient or family Grade 3: disruptive to patient and family; requiring mental health intervention Grade 4: harmful to others or self; requiring hospitalization					HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
Grade 5: death related to toxicity		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	Pyramidal tract dysfunction	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Pyramidal tract dysfunction (e.g., increased tone, hyperreflexia, positive Babinski, decreased fine motor coordination)		1, 2, 3 or 4			HLT:	HLGT:	<u>Pr</u> :		
Grade 1: asymptomatic with abnormality on physical examination Grade 2: symptomatic or interfering with function but not interfering with activities of daily living Grade 3: interfering with activities of daily living		4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :		
Grade 4: bedridden or disabling; paralysis Grade 5: death related to toxicity	Positive Babinski		<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		

			1				1		 
		1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Adverse Event Seizure(s)  N/A Grade 1:	Seizure	2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
Grade 2: seizure(s) self-limited and consciousness is preserved Grade 3: seizure(s) in which consciousness is altered Grade 4: seizures of any type which are prolonged, repetitive, or difficult to control (e.g., status epilepticus, intractable epilepsy)		4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 5: death related to toxicity		4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	Speech impairment	2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		2, 3 or 4	LLT:		HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Speech impairment (e.g., dysphasia or aphasia)		2, 3 or 4	<u>LLT</u> :	<u>PT</u> :					
N/A Grade 1: Grade 2: awareness of receptive or expressive dysphasia, not impairing ability to communicate			<u>LLT</u> :		HLT:	HLGT:	Sec₁:		
Grade 3: receptive or expressive dysphasia, impairing ability to communicate Grade 4: inability to communicate Grade 5: death related to toxicity	Aphasia	2, 3 or 4	<u>LLT</u> :		HLT:	HLGT:	<u>Pr</u> :		
Grade 5: death related to toxicity		2, 3 or 4	LLT:	<u>PT</u> :					
		2, 3 or 4	<u>LLT</u> :		<u>HLT</u> :	HLGT:	Sec <sub>1</sub> :		
Adverse Event Syncope (fainting)  N/A Grade 1: N/A Grade 2: Grade 3: present N/A Grade 4:	Syncope	3	<u>LLT</u> :	- <u>PT</u> :	HLT:	<u>HLGT</u> : Neurological	Pr : Nervous system	SSC1: ARREST	
NA Grade 4:  Grade 5: death related to toxicity  Note: Also consider CARDIOVASCULAR (ARRHYTHMIA), Vasovagal episode, CNS cerebrovascular ischemia.		3	<u>LLT</u> :	<u></u> .	<u>116.1</u> -	disorders NEC	disorders	ARREST (CARDIAC)	

Adverse Event Tremor  Grade 1: mild and brief or intermittent but not interfering with function Grade 2: moderate tremor interfering with function, but not interfering with activities of daily living Grade 3: severe tremor interfering with activities of daily living N/A Grade 4: Grade 5: death related to toxicity	Tremor	1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Vertigo  Grade 1: not interfering with function Grade 2: interfering with function, but not interfering with activities of daily living	Vertigo	1, 2, 3 or	<u>LLT</u> : Vertigo	PT · Vertigo	HLT : Inner ear signs and symptoms	HLGT : Inner ear and VIIIth cranial nerve disorders	Pr : Ear and labyrinth disorders			
Grade 3: interfering with activities of daily living Grade 4: bedridden or disabling Grade 5: death related to toxicity	verago	4	<u>etr</u> . verago	<u>r .</u> . verago	HLT : Vertigos NEC	<u>HLGT</u> : Neurological disorders NEC	Sec. : Nervous system disorders			
Adverse Event Neurology-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
			0	CULAR	/VISUAL					
Toxicity category and code name	Description (reported term)	Grade	LLI	Preferred term MedDRA	нст	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Grade 1: asymptomatic Grade 2: symptomatic, partial visual loss Grade 3: symptomatic, visual loss requiring treatment or interfering with function N/A Grade 4: Grade 5: death related to toxicity	Cataract	1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT :	HLGT:	<u>Pr</u> :			

Adverse Event Conjunctivitis  Grade 1: abnormal ophthalmologic changes, but asymptomatic or symptomatic without visual impairment (i.e., pain and irritation) Grade 2: symptomatic and interfering with function, but not interfering with activities of daily living Grade 3: symptomatic and interfering with activities of daily living N/A Grade 4: Grade 5: death related to toxicity		1, 2 or 3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	만:		
Adverse Event Dry eye  Grade 1: mild, not requiring treatment Grade 2: moderate or requiring artificial tears N/A Grade 3: N/A Grade 4: N/A Grade 5:	Dry eye	1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	만:		
	Glaucoma	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
		1 or 2	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
		3	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Glaucoma  Grade 1: increase in intraocular pressure but no visual loss Grade 2: increase in intraocular pressure with retinal changes		3	<u> </u>	<u></u> .	HLT:	HLGT:	<u>Sec.</u> :		
Grade 3: visual impairment Grade 4: unilateral or bilateral loss of vision (blindness) Grade 5: death related to toxicity		4	<u>LLT</u> :		HLT:	HLGT:	Pr:		
	Bilateral loss of vision		<u>LLT</u> :	. <u>PT</u> :		11651	<u></u> .		
		4	LLT:	EL:	HLT:	HLGT:	<u>Sec.</u> :		
	Keratitis	1, 2, 3 or 4		PT:	HLT:	HLGT :	Pr:		

i	1		1	ı	IEI.	<u> ner</u> -	<u>Incor</u> .	<u>  FL</u> •	ī	i	
			1, 2, 3 or 4	LLT:	_			_			
	Adverse Event Keratitis (corneal inflammation/corneal ulceration)  Grade 1: abnormal ophthalmologic changes but asymptomatic or		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	symptomatic without visual impairment (i.e., pain and irritation)  Grade 2: symptomatic and interfering with function, but not interfering with activities of daily living  Grade 3: symptomatic and interfering with activities of daily living		4	<u>LLT</u> :							
	Grade 4: unilateral or bilateral loss of vision (blindness) Grade 5: death related to toxicity		4	LLT:		<u>HLT</u> :	HLGT:	<u>Pr</u> : Eye disorders			
Category: OCULAR/VISUAL		Blindness	4	LLT:	<u>PT</u> :	HLT : Neurologic visual problems NEC	HLGT : Neurological disorders of the eye	Sec_1: Nervous system disorders			
Category: (	Adverse Event Tearing (watery eyes)  Grade 1: mild: not interfering with function Grade 2: moderate: interfering with function, but not interfering with		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:			
	activities of daily living  Grade 3: interfering with activities of daily living  N/A Grade 4:  Grade 5: death related to toxicity		1, 2 or 3	<u>LLT</u> :	<u></u> .						
	Adverse Event Vision-blurred vision  N/A Grade 1:  Grade 2: symptomatic and interfering with function, but not interfering with	Blurred vision	2 0 2		DT.	HLT:	HLGT:	<u>Pr</u> :			
	activities of daily living <u>Grade 3</u> : symptomatic and interfering with activities of daily living <u>N/A Grade 4</u> : <u>Grade 5</u> : death related to toxicity	Didited Vision	2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Sec.</u> :			
	Adverse Event Vision-double vision (diplopia)  N/A Grade 1:	Double vision		LLT:		HLT:	HLGT:	<u>Pr</u> :			
	Grade 2: symptomatic and interfering with function, but not interfering with				PT:						

activities of daily living  Grade 3: symptomatic and interfering with activities of daily living  N/A Grade 4:				] <u>F1</u> ·					
Grade 5: death related to toxicity		2 or 3	<u>LLT</u> :		<u>HLT</u> :	HLGT:	Sec.:		
Adverse Event Vision-flashing lights/floaters	Flashing lights		LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 1: mild, not interfering with function Grade 2: symptomatic and interfering with function, but not interfering with activities of daily living Grade 3: symptomatic and interfering with activities of daily living N/A Grade 4:					HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
Grade 5: death related to toxicity		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Vision-night blindness (nyctalopia)		1, 2 or 3	<u>LLT</u> :	- <u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Grade 1: abnormal electro-retinography but asymptomatic Grade 2: symptomatic and interfering with function, but not interfering with activities of daily living Grade 3: symptomatic and interfering with activities of daily living N/A Grade 4:	Nyctalopia		<u>LLT</u> :		HLT:	HLGT:	Sec.:		
Grade 5: death related to toxicity			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Vision-photophobia  N/A Grade 1: Grade 2: symptomatic and interfering with function, but not interfering with					HLT:	HLGT:	<u>Pr</u> :		
activities of daily living  Grade 3: symptomatic and interfering with activities of daily living  NA Grade 4:  Grade 5: death related to toxicity			<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Sec.</u> :		
Adverse Event Ocular/Visual-Other (Specify,)									
Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: unilateral or bilateral loss of vision (blindness) Grade 5: death related to toxicity									
				PA	IN				

Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Abdominal pain or cramping  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not	Abdominal pain	1, 2, 3 or 4	<u>LLT</u> :							
interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity		1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> :		
Adverse Event Arthralgia (joint pain)  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living	Arthralgia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:			
Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u></u> .			<u></u> .			
Arthritis (joint pain with clinical signs of inflammation) is graded in the MUSCULOSKELETAL category										
Adverse Event Bone pain  Grade 1: mild pain not interfering with function  Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living  Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living  Grade 4: disabling  Grade 5: death related to toxicity	Bone pain	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC. : PAIN		
Adverse Event Chest pain (non-cardiac and non-pleuritic)		1, 2, 3 or 4	LLT:							
Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living		1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :	<u>SSC</u> 1:	SSC <sub>2</sub> : PAIN	

Grade 4: disabling					1	I	I		]	I
Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :							
Adverse Event Dysmenorrhea  Grade 1: mild pain not interfering with function  Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living  Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living  Grade 4: disabling  Grade 5: death related to toxicity	Dysmenorrhea	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:			
Adverse Event Dyspareunia  Grade 1: mild pain not interfering with function	Dunnania	4.00	LLT:		HLT:	HLGT:	<u>Pr</u> :			
Grade 2: moderate pain interfering with sexual activity Grade 3: severe pain preventing sexual activity N/A Grade 4: Grade 5: death related to toxicity	Dyspareunia	1, 2 or 3	LLT: Dyspareunia	PT: Dyspareunia NOS	HLT:	HLGT:	Sec <sub>1</sub> :			
Dysuria is graded in the RENAL/GENITOURINARY category										
Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not		1, 2, 3 or 4								
interfering with activities of daily living  Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living  Grade 4: disabling  Grade 5: death related to toxicity			<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>1</sub> :		
Adverse Event Headache  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity	Headache	1, 2, 3 or 4	ш:	PI:	HLT:	HLGT:	<u>Pr</u> :	SSC: PAIN		

۹	ζ
1	
:	•
c	_
c	)
C	5
a	٥
ä	3
	١
	מבים בים

Category: PA	Adverse Event Hepatic pain  Grade 1: mild pain not interfering with function  Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living  Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living  Grade 4: disabling  Grade 5: death related to toxicity	Hepatic pain	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<b>HLT</b> :	HLGT:	Pr:	SSC. : PAIN	
	Adverse Event Myalgia (muscle pain)  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity	Myalgia	1, 2, 3 or 4	<u>LLT</u> :	PT:	HLT:	HLGT:	<u>Pr</u> :		
	Adverse Event Neuropathic pain (e.g., jaw pain, neurologic pain, phantom limb pain, post-infectious neuralqia, or painful neuropathies)	Neuropathic pain	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : PAIN	
	Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : PAIN	
	interfering with activities of daily living <u>Grade 3</u> : severe pain: pain or analgesics severely interfering with activities of daily living <u>Grade 4</u> : disabling <u>Grade 5</u> : death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : PAIN	
	Grave 3. death related to toxicity	Neuralgia	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC1: PAIN	
	Adverse Event Pain due to radiation  Grade 1: mild pain not interfering with function  Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living		1, 2, 3 or	шт	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : PAIN	
	Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity		4	<u>:</u>		HLT:	HLGT:	<u>Sec.</u> :	<u>5554</u> . FAIN	

							1		 
Adverse Event Pelvic pain  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity	Pelvic pain	1, 2, 3 or 4	<u>ut</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>ssc.</u> :	
Adverse Event Pleuritic pain  Grade 1: mild pain not interfering with function  Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living  Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living  Grade 4: disabling  Grade 5: death related to toxicity	Pleuritic pain		<u>ur</u> :	<u>PT</u> :	<u>нгт</u> :	<u>HLGT</u> :	<u>Pr</u> :	SSC.:	
Adverse Event Rectal or perirectal pain (proctalgia)  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity		1, 2, 3 or 4 1, 2, 3 or 4 1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC.:	
Adverse Event Tumor pain (onset or exacerbation of tumor pain due to treatment)  Grade 1: mild pain not interfering with function Grade 2: moderate pain: pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain: pain or analgesics severely interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity	Tumor pain	1, 2, 3 or 4	LLT:	PT:	HLT:	HLGT:	Pr:	SSC. : PAIN	
Tumor flair is graded in the SYNDROME category									

Adverse Event Pain-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: disabling										
Grade 5: death related to toxicity				PULMO	NARY					
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Adult respiratory distress syndrome (ARDS)  N/A Grade 1: N/A Grade 2: N/A Grade 3: Grade 4: present Grade 5: death related to toxicity	Adult respiratory distress syndrome	4	шт	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Apnea  N/A Grade 1: N/A Grade 2: Grade 3: present Grade 4: requiring intubation Grade 5: death related to toxicity	Apnea	3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:			
Adverse Event Carbon monoxide diffusion capacity (DL(co))  Grade 1: >= 75 - <90% of pretreatment or normal value Grade 2: >= 50 - <75% of pretreatment or normal value Grade 3: >= 25 - <50% of pretreatment or normal value Grade 4: <25% of pretreatment or normal value Grade 5: death related to toxicity	Carbon monoxide diffusion capacity (DL(co))	1, 2, 3 or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:			
Adverse Event Cough  Grade 1: mild, relieved by non-prescription medication Grade 2: requiring narcotic antitussive Grade 3: severe cough or coughing spasms, poorly controlled or unresponsive to treatment N/A Grade 4: Grade 5: death related to toxicity	Cough	1, 2 or 3	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Dyspnea (shortness of breath)	Dyspnea	2, 3 or 4	LLT:	PT :	HLT:	HLGT : Respiratory disorders NEC	Pr : Respiratory, thoracic and mediastinal disorders	SSC1:	SSC <sub>2</sub> :	

N/A Grade 1:		2, 3 or 4	LLT:	<u>F1</u> ·	HLT:	HLGT : Cardiac disorder	Sec_1 : Cardiac disorders	ANAFRILAAI S	ISCHAEMIA	
Grade 2: dyspnea on exertion Grade 3: dyspnea at normal level of activity Grade 4: dyspnea at rest or requiring ventilator support		_, -,			HLT:	signs and symptoms <u>HLGT</u> :	<u>Pr</u> :			
Grade 5: death related to toxicity			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :	<u>SSC₁</u> :		
Adverse Event FEV (1)  Grade 1: >= 75 - <90% of pretreatment or normal value Grade 2: >= 50 - <75% of pretreatment or normal value Grade 3: >= 25 - <50% of pretreatment or normal value Grade 4: <25% of pretreatment or normal value Grade 5: death related to toxicity	FEV (1)	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Hiccoughs (hiccups, singultus)		1, 2 or 3	<u>LLT</u> :		HLT:	HLGT:	Pr : Gastrointestinal disorders			
Grade 1: mild, not requiring treatment Grade 2: moderate, requiring treatment Grade 3: severe, prolonged and refractory to treatment N/A Grade 4: Grade 5: death related to toxicity		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :						
		1, 2 or 3	<u>LLT</u> :		HLT:	HLGT:	Sec <sub>1</sub> :			
Adverse Event Hypoxia  N/A Grade 1: Grade 2: decreased O2 saturation with exercise Grade 3: decreased O2 saturation at rest, requiring supplementa		2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grade 4: decreased O2 saturation, requiring pressure support (C assisted ventilation Grade 5: death related to toxicity	PAP) or	2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Adverse Event Pleural effusion (non-malignant)  Grade 1: asymptomatic and not requiring treatment Grade 2: symptomatic, requiring diuretics Grade 3: symptomatic, requiring O2 or therapeutic thoracentesis Grade 4: life-threatening (e.g., requiring intubation) Grade 5: death related to toxicity	Pleural effusion (non-malignant)	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	Pr:			
Pleuritic pain is graded in the PAIN category										

Adverse Event Pneumonitis/pulmonary infiltrates  Grade 1: radiographic changes but asymptomatic or symptoms not requiring steroids  Grade 2: radiographic changes and requiring steroids or diuretics  Grade 3: radiographic changes and requiring oxygen  Grade 4: radiographic changes and requiring assisted ventilation  Grade 5: death related to toxicity	Pneumonitis/pulm onary infiltrates	1, 2, 3 or 4		<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Pneumothorax  Grade 1: no intervention required Grade 2: chest tube required Grade 3: sclerosis or surgery required Grade 4: life-threatening Grade 5: death related to toxicity	Pneumothorax	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Pulmonary embolism is graded as Thrombosis/embolism in the CARDIOVASCULAR (GENERAL) category									
Adverse Event Pulmonary fibrosis  Grade 1: radiographic changes, but asymptomatic or symptoms not requiring steroids or diuretics Grade 2: requiring steroids or diuretics Grade 3: requiring oxygen Grade 4: requiring assisted ventilation Grade 5: death related to toxicity  Note: Radiation-related pulmonary fibrosis is graded in the RTOG/EORTC Late Radiation Morbidity Scoring Scheme-Lung (see Appendix IV).	Pulmonary fibrosis		LLT : Pulmonary fibrosis	PT: Pulmonary fibrosis	HLT : Parenchymal lung disorders NEC	HLGT: Lower respiratory tract disorders (excl obstruction and infection)	Pr : Respiratory, thoracic and mediastinal disorders		
	Voice changes/stridor/la rynx (e.g.,	1, 2, 3 or		DT -	HLT:	HLGT:	<u>Pr</u> :		
Adverse Event Voice changes/stridor/larynx (e.g., hoarseness, loss of voice, laryngitis)	hoarseness, loss of voice, laryngitis)	4	<u>LL1</u> :	<u>PT</u> :	HLT:	HLGT:	Sec <sub>1</sub> :		
Grade 1: mild or intermittent hoarseness Grade 2: persistent hoarseness, but able to vocalize; may have mild to moderate edema		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :	SSC <sub>1</sub> : ANAPHYLAXI S	
Grade 3: whispered speech, not able to vocalize; may have marked edema Grade 4: marked dyspnea/stridor requiring tracheostomy or intubation Grade 5: death related to toxicity		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Note: Cough from radiation is graded as cough in the PULMONARY category. Radiation-related hemoptysis from larynx/pharynx is graded as Grade 4 Mucositis due to radiation in the GASTROINTESTINAL	Loss of voice	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
category. Radiation-related hemoptysis from the thoracic cavity is graded as Grade 4 Hemoptysis in the HEMORRHAGE category.					HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
		1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		

Adverse Event Pulmonary-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
RENAL/GENITOURINARY										
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Adverse Event Bladder spasms  Grade 1: mild symptoms, not requiring intervention Grade 2: symptoms requiring antispasmodic Grade 3: severe symptoms requiring narcotic N/A Grade 4: Grade 5: death related to toxicity	Bladder spasms	1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	Pr:			
Adverse Event Creatinine  Grade 1: > ULN - 1.5 x ULN Grade 2: > 1.5 - 3.0 x ULN Grade 3: > 3.0 - 6.0 x ULN Grade 4: > 6.0 x ULN Grade 5: death related to toxicity  Note: Adjust to age-appropriate levels for pediatric patients.	Creatinine	1, 2, 3 or 4	LLT:	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
Adverse Event Dysuria (painful urination)  Grade 1: mild symptoms requiring no intervention Grade 2: symptoms relieved with therapy		1, 2 or 3	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
Grade 3: symptoms not relieved despite therapy N/A Grade 4: Grade 5: death related to toxicity		1, 2 or 3	LLT:	<u></u> -						
Adverse Event Fistula or GU fistula (e.g., vaginal, vesicovaginal)  N/A Grade 1: N/A Grade 2: Grade 3: requiring intervention Grade 4: requiring surgery Grade 5: death related to toxicity	Fistula or GU fistula (e.g., vaginal, vesicovaginal)	3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
					HLT:	HLGT:	Sec <sub>1</sub> :			

_										
G N N	dverse Event Hemoglobinuria rade 1: present /A Grade 2: /A Grade 3: /A Grade 4: /A Grade 5:	Hemoglobinuria	1	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	ematuria (in the absence of vaginal bleeding) is graded in the EMORRHAGE category									
						HLT:	HLGT:	<u>Pr</u> :		
	dverse Event Incontinence	Incontinence	1, 2 or 3	LLT: Incontinence	PT: Incontinence NOS	HLT:	HLGT:	Sec <sub>1</sub> :		
G	rade 1: with coughing, sneezing, etc. rade 2: spontaneous, some control rade 3: no control (in the absence of fistula)  A Grade 4:					HLT : Autonomic nervous system disorders	HLGT : Neuromuscular disorders	Sec <sub>2</sub> : Nervous system disorders		
	rade 5: death related to toxicity			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
						<u>HLT</u> :	HLGT:	Sec₁:		
NG G or G di	dverse Event Operative injury to bladder and/or ureter  (A Grade 1: rade 2: injury of bladder with primary repair rade 3: sepsis, fistula, or obstruction requiring secondary surgery; loss of ne kidney; injury requiring anastomosis or re-implantation rade 4: septic obstruction of both kidneys or vesicovaginal fistula requiring version rade 5: death related to toxicity	Operative injury to bladder and/or ureter	2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	Pr:		
GG	rade 2: 2+ to 3+ or 1.0 - 3.5 g/24 hour rade 3: 4+ or > 3.5 g/24 hour	Proteinuria	1, 2, 3 or 4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
G N	rade 4: nephrotic syndrome rade 5: death related to toxicity  ote: If there is an inconsistency between absolute value and dip stick lading, use the absolute value for grading.			<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	<u>SSC</u> <sub>1</sub> :	
N N G	dverse Event Renal failure  /A Grade 1: /A Grade 2: rade 3: requiring dialysis, but reversible rade 4: requiring dialysis and irreversible rade 5: death related to toxicity	Renal failure	3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :	SSC1: SECONDARY IMMUNOCOM PROMISED STATE	

С	)
~	i
đ	٥
+	٠
π	j
"	۱

	erse Event Ureteral obstruction	Ureteral obstruction		<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
N/A Gra Gra	te 1: unilateral, not requiring surgery  Grade 2:  6 3: bilateral, not requiring surgery  de 4: stent, nephrostomy tube, or surgery		4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Gra	de 5: death related to toxicity	Ureteral stent	4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	<u>HLGT</u> :	<u>Pr</u> :		
	erse Event Urinary electrolyte wasting (e.g., Fanconi's syndrome, renal	Urinary electrolyte wasting	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
Gra	de 1: asymptomatic, not requiring treatment	Fanconi's	1, 2, 3 or	LLT : Fanconi	PT : Fanconi	HLT:	<u>HLGT</u> :	<u>Pr</u> :		
Gra Gra	be 3: reversible but requiring IV replacement be 4: irreversible, requiring continued replacement be 5: death related to toxicity	syndrome	4	syndrome	acquired	HLT:	HLGT:	Sec <sub>1</sub> :		
Note	e: Also consider Acidosis, Bicarbonate, Hypocalcemia, ophosphatemia.			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
						HLT:	HLGT:	Sec <sub>1</sub> :		
Adv	erse Event Urinary frequency/urgency	Urinary frequency/urgenc y	1, 2 or 3	<u>LLT</u> :	- <u>PT</u> :	HLT:	HLGT:	Pr:		
Gra Gra N/A	de 1: increase in frequency or nocturia up to 2 x normal de 2: increase > 2 x normal but < hourly de 3: hourly or more with urgency, or requiring catheter Grade 4:		1, 2 or 3	<u>LLT</u> :	<u>F1</u> .	<u>nc.</u> .	neor.	<u> </u>		
Gra	de 5: death related to toxicity		1, 2 or 3	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	erse Event Urinary retention de 1: hesitancy or dribbling, but no significant residual urine; retention	Urinary retention	1, 2, 3 or 4	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
occu Gra (<4 beyon Gra urolo	urring during the immediate postoperative period  16 2: hesitancy requiring medication or occasional in/out catheterization  x per week), or operative bladder atony requiring indwelling catheter  ond immediate postoperative period but for <6 weeks  16 3: requiring frequent in/out catheterization (>= 4 x per week) or  gical intervention (e.g., TURP, suprapubic tube, urethrotomy)			LLT:	DT .	HLT:	HLGT : Injuries NEC	Pr: injury, poisoning and procedural complications		
	<ul> <li>de 4: bladder rupture</li> <li>de 5: death related to toxicity</li> </ul>			<u>: : : : : : : : : : : : : : : : : : : </u>	<u>PT</u> :	HLT:	HLGT: Bladder and bladder neck disorders (excl calculi)	Sec. : Renal and urinary disorders		

	Adverse Event Urine color change (not related to other dietary or physiologic cause e.g., bilirubin, concentrated urine, hematuria)										
	Grade 1: asymptomatic, change in urine color N/A Grade 2:	Urine color change	1	<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Vaginal bleeding is graded in the HEMORRHAGE category										
	Adverse Event Vaginitis (not due to infection)  Grade 1: mild, not requiring treatment Grade 2: moderate, relieved with treatment Grade 3: severe, not relieved with treatment, or ulceration not requiring	Vaginitis	1, 2, 3 or	<u>LLT</u> : Vaginitis	PT · Vaginitie	HLT : Female reproductive tract infections	HLGT : Infections - pathogen class unspecified	Pr : Infections and infestations			
	Grade 4: ulceration requiring surgery Grade 5: death related to toxicity	vagillus	4	<u></u>	- vagiillis	HLT : Vaginal and vulval infections and inflammations	HLGT : Female reproductive tract infections and inflammations	Sec. : Reproductive system and breast disorders			
	Adverse Event Renal/Genitourinary-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
				SECON	DARY I	MALIGNANCY					
	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	нст	шст	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Category: SECONDARY MALIGNANCY	Adverse Event Secondary Malignancy-Other (Specify,) excludes metastasis from initial primary  N/A Grade 1:  N/A Grade 2:  N/A Grade 3:  Grade 4: present  N/A Grade 5:										
			SEX	KUAL/RE	PRODU	CTIVE FUNCTION					

	Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Dyspareunia is graded in the PAIN category										
	Dysmenorrhea is graded in the PAIN category										
	Adverse Event Erectile impotence  Grade 1: mild (erections impaired but satisfactory)  Grade 2: moderate (erections impaired, unsatisfactory for intercourse)			LLT:	<u>PT</u> :	HLT : Erection and ejaculation conditions and disorders	HLGT : Sexual function and fertility disorders	Pr: Reproductive system and breast disorders			
	Grade 3: no erections N/A Grade 4: Grade 5: death related to toxicity			<u>LLT</u> :	<u>rı</u> :	HLT : Sexual arousal disorders	HLGT : Sexual function and fertility disorders	Sec_1 : Psychiatric disorders			
	Adverse Event Female sterility  N/A Grade 1: N/A Grade 2: Grade 3: sterile N/A Grade 4: Grade 5: death related to toxicity	Female sterility	3	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	Femininization of male is graded in the ENDOCRINE category										
	Adverse Event Irregular menses (change from baseline)	Irregular menses	1 2 or 2	LLT : Menses	PT:	HLT:	HLGT:	<u>Pr</u> :			
	Grade 1: occasionally irregular or lengthened interval, but continuing menstrual cycles Grade 2: very irregular, but continuing menstrual cycles	megulai menses	1, 2 01 3	irregular	irregular	HLT:	HLGT:	<u>Sec.</u> :			
LION	Grade 2: very megual, but community mensitual cycles  Grade 3: persistent amenorrhea  MA Grade 4:  Grade 5: death related to toxicity			LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
FUNC	- Countributed to tonony			<u>LLI</u> .	<u></u>	HLT:	HLGT:	<u>Sec.</u> :			
DUCTIVE	Adverse Event Libido  Grade 1: decrease in interest  Grade 2: severe loss of interest		1 or 2			HLT : Sexual desire disorders	HLGT: Sexual dysfunctions, disturbances and gender identity disorders	Pr : Psychiatric disorders			
SEXUAL/REPRODUCTIVE FUNCTION	N/A Grade 3: N/A Grade 4: N/A Grade 5:		, OI 2	<u>LLT</u> :	<u>PT</u> :	HLT : Sexual function and fertility disorders NEC	HLGT : Sexual function and fertility disorders	Sec <sub>1</sub> : Reproductive system and breast disorders			
: SEXU	Adverse Event Male infertility			<u>LLT</u> :	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			

Grad M/A	. Grade 1: ude 2: oligospermia (low sperm count) ude 3: azoospermia (no sperm) . Grade 4:			<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
පී <u>Gra</u>	tide 5: death related to toxicity			LLT:	_			_			
Mas	sculinization of female is graded in the ENDOCRINE category										
	verse Event Vaginal dryness	Vaginal dryness	1 or 2	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
Grad dysp N/A	ide 1: mild tide 2: requiring treatment and/or interfering with sexual function, pareunia . Grade 3: . Grade 4:			LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
	Grade 5:			-		HLT:	HLGT:	<u>Sec.</u> :			
Grad Grad Grad Grad	verse Event Sexual/Reproductive Function-Other (Specify,)  ude 1: mild  ude 2: moderate  ude 3: severe  ude 4: disabling  ude 5: death related to toxicity										
		SYNI	DROM	IES (not	include	d in previous categor	ies)				
Tox	xicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
Acu	ute vascular leak syndrome is graded in the CARDIOVASCULAR	Acute vascular	2, 3 or 4	шт	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
(GE	NERAL) category	leak syndrome	2, 0 01 4		<u></u> .	HLT:	HLGT:	<u>Sec.</u> :			
	DS (Adult Respiratory Distress Syndrome) is graded in the LMONARY category		4	LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :			
	coimmune reactions are graded in the ALLERGY/IMMUNOLOGY egory		1, 2, 3, or 4	LLT:	<u>PT</u> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	: (disseminated intravascular coagulation) is graded in the	DIC	3 or 4	LLT : DIC	PT: Disseminated	HLT:	HLGT:	<u>Pr</u> :			
COA	AGULATION category		- 0	- 5.0	intravascular coagulation	<u>HLT</u> :	HLGT:	Sec <sub>1</sub> :			

	Fanconi's syndrome is graded as Urinary electrolyte wasting in the	Fanconi's	1, 2, 3 or	LLT : Fanconi	PT : Fanconi	HLT:	HLGT:	<u>Pr</u> :		
		syndrome	4	syndrome	acquired	HLT:	HLGT:	Sec. :		
	Renal tubular acidosis is graded as Urinary electrolyte wasting in the			LLT:	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
	RENAL/GENITOURINARY category			<u>LL1</u> .		HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
	Stevens-Johnson syndrome (erythema multiforme) is graded in the		2, 3 or 4	шт	PT:	<u>HLT</u> :	HLGT:	<u>Pr</u> :		
	DERMATOLOGY/SKIN category		2,0014			HLT:	<u>HLGT</u> :	<u>Sec₁</u> :		
	SIADH (syndrome of inappropriate antidiuretic hormone) is graded in the ENDOCRINE category		3	If you	need to set	a complete mapping version (C please contact Phar 112, rue Olivier de 75015 Paris Tel: +33 (0)8 71 76 Tel: +33 (0)6 73 51 or send an email to info@pl	madhoc Serres 8 88 17 37 96	.0 - MedDRA),		
				<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
						HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :		
IES						HLT:	HLGT:	<u>Pr</u> :		
IDRO	Thrombotic microangiopathy (e.g., thromboitic thrombocytopenic purpura/TTP or hemolytic uremic syndrom/HUS) is graded in the		3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Sec</u> <sub>1</sub> :	SSC <sub>1</sub> :	
y: SYN	COAGULATION category					<u>HLT</u> :	HLGT:	Sec <sub>2</sub> :		
Category: SYNDROMES				LLT:				<del></del>		
ပိ			3 or 4	<u>LLT</u> :	<u>PT</u> :	HLT:	HLGT:	<u>Pr</u> :		
				<u>LLT</u> :		HLT:	HLGT:	<u>Sec.</u> :		

Adverse Event Tumor flare  Grade 1: mild pain not interfering with function Grade 2: moderate pain; pain or analgesics interfering with function, but not interfering with activities of daily living Grade 3: severe pain; pain or analgesics interfering with function and interfering with activities of daily living Grade 4: disabling Grade 5: death related to toxicity  Note: Tumor Flare is characterized by a constellation of symptoms and signs in direct relation to initiation of therapy (e.g., antiestrogens/androgens or additional hormones). The symptoms/signs include tumor pain, inflammation of visible tumor, hypercalcemia, diffuse bone pain, and other electrolyte disturbances. Also consider Hypercalcemia.  Attribution Code Unrelated Unlikely Possible Probable Definite	Tumor flare	1, 2, 3 or 4	<u>LLT</u> :	<b>PI</b> :	<u>HLT</u> :	HLGT:	<u>Pr</u> :			
	Tumor lysis	3	LLT:	PT:	HLT:	HLGT:	<u>Pr</u> :			
N/A Grade 4: Grade 5: death related to toxicity  Note: Also consider Hyperkalemia, Creatinine.	syndrome		-		HLT:	HLGT:	<u>Sec.</u> :			
Urinary electrolyte wasting (e.g., Fanconi's syndrome, renal tubular acidosis) is graded under the RENAL/GENITOURINARY category										
Adverse Event Syndromes-Other (Specify,)  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening or disabling Grade 5: death related to toxicity										
Appendix IV RTOG/EORTC Late Radiation	on Morbid	lity So	coring S	cheme ( thera		ts occurring gre	ater than 90 d	lays afte	r radiation	on
Toxicity category and code name	Description (reported term)	Grade	LLT MedDRA	Preferred	нцт	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3

			1	1	T.	1	1		
	Adverse Event Bladder- Late RT Morbidity Scoring  Grade 1: Slight epithelial atrophy/minor telangiectasia (microscopic hematuria)  Grade 2: Moderate frequency/generalized telangiectasia/intermittent macroscopic hematuria  Grade 3: Severe frequency and dysuria/severe generalized telangiectasia (often with petechiae); frequent hematuria; reduction in bladder capacity (<150mL)  Grade 4: Necrosis/contracted bladder (capacity <100 mL) severe hemorrhagic cystitis  Grade 5: death related to adverse event								
	Adverse Event Bone - Late RT Morbidity Scoring  Grade 1: Asymptomatic; no growth retardation; reduced bone density Grade 2: Moderate pain or tenderness; growth retardation; irregular bone sclerosis Grade 3: Severe pain or tenderness; complete arrest of bone growth; dense bone sclerosis Grade 4: Necrosis/spontaneous fracture Grade 5: death related to adverse event								
radiation therapy.)	Adverse Event Brain- Late RT Morbidity Scoring  Grade 1: Mild headache; slight lethargy Grade 2: Moderate headache; great lethargy Grade 3: Severe headaches; severe CNS dysfunction (partial loss of power or dyskinesia) Grade 4: Seizures or paralysis; coma Grade 5: death related to adverse event								
eater than 90 days after ra	Adverse Event Esophagus- Late RT Morbidity Scoring  Grade 1: Mild fibrosis; slight difficulity in swallowing solids; no pain on swallowing  Grade 2: Unable to take solid food normally; swallowing semi-solid food; dilation may be indicated  Grade 3: Severe fibrosis; able to swallow only liquids; may have pain on swallowing; dilation required  Grade 4: Necrosis/perforation; fistula  Grade 5: death related to adverse event								

adverse events occurring gr	Adverse Event Eye- Late RT Morbidity Scoring  Grade 1: Asymptomatic cataract; minor corneal ulceration or keratitis Grade 2: Symptomatic cataract; moderate corneal ulceration; minor retinopathy or glaucoma Grade 3: Severe keratitis; severe retinopathy or detachment; severe glaucoma Grade 4: Panophthalmitis; blindness Grade 5: death related to adverse event					
Scoring Scheme (Use for ad	Adverse Event Heart- Late RT Morbidity Scoring  Grade 1: Asymptomatic or mild symptoms; transient T wave inversion and ST changes; sinus tachycardia >110 (at rest) Grade 2: Moderate angina on effort; mild pericarditis; normal heart size; persistent abnormal T wave and ST changes; low QRS Grade 3: Severe angina; pericardial effusion; constrictive pericarditis; moderate heart failure; cardiac enlargement; EKG abnormalities Grade 4: Tamponade/severe heart failure/severe constrictive pericarditis Grade 5: death related to adverse event					
Radiation Morbidity	Adverse Event Joint- Late RT Morbidity Scoring  Grade 1: Mild joint stiffness; slight limitation of movement Grade 2: Moderate stiffness; intermittent or moderate joint pain; moderate limitation of movement Grade 3: Severe joint stiffness; pain with severe limitation of movement Grade 4: Necrosis/complete fixation Grade 5: death related to adverse event					
Appendix IV RTOG/EORTC Late	Adverse Event Kidney-Late RT Morbidity Scoring  Grade 1: Transient albuminuria; no hypertension; mild impairment of renal function; urea 25-35 mg%; creatinine 1.5-2.0 mg%; creatinine clearance >75%  Grade 2: Persistent moderate albuminuria (2+); mild hypertension; no related anemia; moderate impairment of renal function; urea >36-60 mg%; creatinine clearance >50-74%  Grade 3: Severe albuminuria; severe hypertension; persistent anemia (<10 g%); severe renal failure; urea >60 mg%; creatinine >4 mg%; creatinine clearance <50%  Grade 4: Malignant hypertension; uremic coma/urea >100%  Grade 5: death related to adverse event					

s after radiation therapy.)Category:	Adverse Event Larynx-Late RT Morbidity Scoring  Grade 1: Hoarseness; slight arytenoid edema Grade 2: Moderate arytenoid edema; chondritis Grade 3: Severe edema; severe chondritis Grade 4: Necrosis Grade 5: death related to adverse event					
day	Adverse Event Liver-Late RT Morbidity Scoring  Grade 1: Mild lassitude; nausea; dyspepsia; slightly abnormal liver function frade 2: Moderate symptoms; some abnormal liver function tests; serum albumin normal  Grade 3: Disabling hepatic insufficiency; liver function tests grossly abnormal; low albumin; edema or ascites  Grade 4: Necrosis/hepatic coma or encephalopathy  Grade 5: death related to adverse event					
Scoring Scheme (Use for adverse events occurring greater than 90	Adverse Event Lung-Late RT Morbidity Scoring  Grade 1: Asymptomatic or mild symptoms (dry cough); slight radiographic appearances Grade 2: Moderate symptomatic fibrosis or pneumonitis (severe cough); low grade fever; patchy radiographic appearances Grade 3: Severe symptomatic fibrosis or pneumonitis; dense radiographic changes Grade 4: Severe respiratory insufficiency/continuous O(2)/assisted ventilation Grade 5: death related to adverse event					
cheme (Use for advers	Adverse Event Mucous membrane-Late RT Morbidity Scoring  Grade 1: Slight atrophy and dryness  Grade 2: Moderate atrophy and telangiectasia; little mucus  Grade 3: Marked atrophy with complete dryness; severe telangiectasia  Grade 4: Ulceration  Grade 5: death related to adverse event					
n Morbidity Scoring S	Adverse Event Salivary glands-Late RT Morbidity Scoring  Grade 1: Slight dryness of mouth; good response on stimulation  Grade 2: Moderate dryness of mouth; poor response on stimulation  Grade 3: Complete dryness of mouth; no response on stimulation  Grade 4: Fibrosis  Grade 5: death related to adverse event					

Jiatio	Adverse Event Skin-Late RT Morbidity Scoring								
ORTC Late Rac	Grade 1: Slight atrophy; pigmentation change; some hair loss Grade 2: Patchy atrophy; moderate telangiectasia; total hair loss Grade 3: Marked atrophy; gross telangiectasia Grade 4: Ulceration Grade 5: death related to adverse event								
Category: Appendix IV RTOG/EORTC Late Radiatio	Adverse Event Small/Large intestine-Late RT Morbidity Scoring  Grade 1: Mild diarrhea; mild cramping; bowel movement 5 x daily; slight rectal discharge or bleeding Grade 2: Moderate diarrhea and colic; bowel movement >5 x daily; excessive rectal mucus or intermittent bleeding Grade 3: Obstruction or bleeding, requiring surgery Grade 4: Necrosis/perforation; fistula Grade 5: death related to adverse event								
Catego	Adverse Event Spinal cord-Late RT Morbidity Scoring  Grade 1: Mild Lhermitte's syndrome Grade 2: Severe Lhermitte's syndrome Grade 3: Objective neurological findings at or below cord level treatment Grade 4: Mono-, para-, quadriplegia Grade 5: death related to adverse event								
	Adverse Event Subcutaneous tissue-Late RT Morbidity Scoring  Grade 1: Slight induration (fibrosis) and loss of subcutaneous fat Grade 2: Moderate fibrosis but asymptomatic; slight field contracture; <10% linear reduction Grade 3: Severe induration and loss of subcutaneous tissue; field contracture >10% linear measurement Grade 4: Necrosis Grade 5: death related to adverse event								
	Adverse Event Radiation-Other(Specify,)  Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening or disabling Grade 5: death related to adverse event								
		Appe	ndix \	VI BMT C	Complex	/Multicomponent Eve	ents		

	Toxicity category and code name	Description (reported term)	Grade	LL I	Preferred term MedDRA	HLT	HLGT	Pr = Primary SOC Sec <sub>n</sub> = Secondary SOC	SSC1	SSC2	SSC3
	Note: The grading of Complex/Multicomponent Events in bone marrow transplant will be defined in the protocol. The grading scale must use the CTC criteria for grading the specific component events (toxicities). Category: Appendix VI BMT Complex/Multicomponent Events										
	Adverse Event Failure to engraft  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening Grade 5: death related to adverse event  Note: Also consider Hemoglobin, Neutrophils/granulocytes (ANC/AGC), Neutrophils/granulocytes (ANC/AGC) for BMT studies, if specified in the protocol, Platelets, Platelets for BMT studies, if specified in the protocol.										
plex/Multicomponent Events	Adverse Event Graft versus host disease  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening Grade 5: death related to adverse event  Note: Also consider Fatigue, Rash/desquamation, Rash/desquamation	Graft versus host 1, 3 disease 4	4	versus host	PT : Graft versus host disease	HLT : Transplant rejections	HLGT : Immune disorders NEC	Pr : Immune system disorders	SSC.: SECONDARY IMMUNOCOM PROMISED STATE		
	associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Diarrhea patients without a colostomy, Diarrhea patients with a colostomy, Diarrhea patients with a colostomy, Diarrhea patients with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Diarrhea for pediatric BMT studies, if specified in the protocol, Bilirubin, Bilirubin associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol.					HLT : Non-site specific procedural complications	<u>HLGT</u> : Procedural and device related injuries and complications NEC	Sec. : Injury, poisoning and procedural complications			

Category: Appendix VI BMT Com	Adverse Event Stem cell infusion complications  Grade 1: mild Grade 2: moderate Grade 3: severe Grade 4: life-threatening Grade 5: death related to adverse event  Note: Also consider Allergic reaction/ hypersensitivity, Conduction abnormality/Atrioventricular heart block, Noda/junctional arrhythmia/dysrhythmia, Prolonged QTc interval (QTc >0.48 seconds), Sinus bradycardia, Sinus tachycardia, Supraventricular arrhythmias (SVT/atrial fibrillation/flutter), Vasovagal episode, Ventricular arrhythmia (PVCs/bigeminy/trigeminy/ventricular tachycardia), Cardiovascular/Arrhythmia-Other (Specify,), Hypertension, Hypotension, Fever (in the absence of neutropenia, where neutropenia is defined as AGC <1.0 x 109/L), Rigors/chills, Sweating (diaphoresis), Rash/desquamation, Rasociated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol, Urticaria (hives, welts, wheals), Diarrhea patients without a colostomy, Diarrhea patients with a colostomy, Diarrhea associated with graft versus host disease (GVHD) for BMT studies, if specified in the protocol								
	Adverse Event Veno-Occlusive Disease (VOD)  Grade 1: mild  Grade 2: moderate  Grade 3: severe  Grade 4: life-threatening  Grade 5: death related to adverse event  Note: Also consider Weight gain associated with Veno-Occlusive Disease (VOD) for BMT studies, if specified in the protocol, Bilirubin, Bilirubin associated with graft versus host disease (GVHD) for BMT  studies, if specified in the protocol, Depressed level of consciousness, Hepatic pain, Renal failure, Hepatic enlargement.	Veno-Occlusive Disease (VOD)	1, 2, 3 or 4	LLT: Venoocclusive disease NOS	HLT : Non-site specific vascular disorders NEC	HLGT : Vascular disorders NEC	<u>Pr</u> : Vascular disorders		